<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25432964</PMID>
        <DateCreated>
            <Year>2015</Year>
            <Month>01</Month>
            <Day>28</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0929</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>143</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2015</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicological sciences : an official journal of the Society of Toxicology</Title>
                <ISOAbbreviation>Toxicol. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cyclooxygenase-1 serves a vital hepato-protective function in chemically induced acute liver injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn>430-40</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1093/toxsci/kfu244</ELocationID>
            <Abstract>
                <AbstractText>Cyclooxygenase-1 (COX-1) is the constitutive form of the COX enzyme family, which produces bioactive lipids called prostanoids. Although the role of COX-2 in liver diseases has been studied, little is known about the function of COX-1 in liver injury. We aimed to investigate the role and mechanism of COX-1 in acute liver injury. Carbon tetrachloride (CCl(4)) was administered to induce acute liver injury in wild-type or COX-1-deficient mice. Both genetic (partially or completely) deletion of COX-1 expression and pharmacological inhibition of COX-1 activity in mice exacerbated acute liver injury induced by CCl(4), revealing the (1) histopathological changes and increased serum levels of aminotransferases; (2) oxidative stress in the liver partly through the action of cytochrome P450 2E1-dependent pathway; (3) enhanced inflammatory and chemoattractive responses with increased number of activated macrophages; and (4) increased apoptosis through both intrinsic and extrinsic apoptotic pathways. These pathological changes were partly through the modulation of transcription factor-dependent pathways (eg, NF-κB and C/EBP-α). Pre-treatment with prostaglandin E2 (PGE(2)) or 5-lipoxygenase (5-LO) inhibitor in homozygous COX-1 knockout mice significantly ameliorated CCl(4)-induced hepatic injury. In addition, level of hepato-protective molecules (eg, OSM and OSMR) and associated liver regeneration pathway were significantly inhibited by the deficiency of COX-1 but restored by the addition of PGE(2) or the inhibition of 5-LO. Furthermore, the alternative arachidonic acid metabolism pathway of 5-LO, which induced additional inflammation in the liver, was activated in response to the deficiency of COX-1. In conclusion, basal expression of COX-1 is essential for the protection of liver against chemical-induced hepatotoxicity and required for hepatic homeostatic maintenance.</AbstractText>
                <CopyrightInformation>© The Author 2014. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Xiao</LastName>
                    <ForeName>Jia</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>*Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, 510632 China, Department of Anatomy and Department of Physiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China and Department of Pathology and Laboratory Medicine, Dalhousie University School of Medicine, Halifax, B3H 4R2 Canada *Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, 510632 China, Department of Anatomy and Department of Physiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China and Department of Pathology and Laboratory Medicine, Dalhousie University School of Medicine, Halifax, B3H 4R2 Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liong</LastName>
                    <ForeName>Emily C</ForeName>
                    <Initials>EC</Initials>
                    <AffiliationInfo>
                        <Affiliation>*Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, 510632 China, Department of Anatomy and Department of Physiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China and Department of Pathology and Laboratory Medicine, Dalhousie University School of Medicine, Halifax, B3H 4R2 Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Hai</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>*Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, 510632 China, Department of Anatomy and Department of Physiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China and Department of Pathology and Laboratory Medicine, Dalhousie University School of Medicine, Halifax, B3H 4R2 Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>On Tse</LastName>
                    <ForeName>Wing</ForeName>
                    <Initials>W</Initials>
                    <AffiliationInfo>
                        <Affiliation>*Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, 510632 China, Department of Anatomy and Department of Physiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China and Department of Pathology and Laboratory Medicine, Dalhousie University School of Medicine, Halifax, B3H 4R2 Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lau</LastName>
                    <ForeName>Kam Shing</ForeName>
                    <Initials>KS</Initials>
                    <AffiliationInfo>
                        <Affiliation>*Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, 510632 China, Department of Anatomy and Department of Physiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China and Department of Pathology and Laboratory Medicine, Dalhousie University School of Medicine, Halifax, B3H 4R2 Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pan</LastName>
                    <ForeName>Jingfei</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>*Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, 510632 China, Department of Anatomy and Department of Physiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China and Department of Pathology and Laboratory Medicine, Dalhousie University School of Medicine, Halifax, B3H 4R2 Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nanji</LastName>
                    <ForeName>Amin A</ForeName>
                    <Initials>AA</Initials>
                    <AffiliationInfo>
                        <Affiliation>*Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, 510632 China, Department of Anatomy and Department of Physiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China and Department of Pathology and Laboratory Medicine, Dalhousie University School of Medicine, Halifax, B3H 4R2 Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fung</LastName>
                    <ForeName>Man Lung</ForeName>
                    <Initials>ML</Initials>
                    <AffiliationInfo>
                        <Affiliation>*Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, 510632 China, Department of Anatomy and Department of Physiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China and Department of Pathology and Laboratory Medicine, Dalhousie University School of Medicine, Halifax, B3H 4R2 Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xing</LastName>
                    <ForeName>Feiyue</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>*Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, 510632 China, Department of Anatomy and Department of Physiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China and Department of Pathology and Laboratory Medicine, Dalhousie University School of Medicine, Halifax, B3H 4R2 Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tipoe</LastName>
                    <ForeName>George L</ForeName>
                    <Initials>GL</Initials>
                    <AffiliationInfo>
                        <Affiliation>*Department of Immunobiology, Institute of Tissue Transplantation and Immunology, Jinan University, Guangzhou, 510632 China, Department of Anatomy and Department of Physiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China and Department of Pathology and Laboratory Medicine, Dalhousie University School of Medicine, Halifax, B3H 4R2 Canada tgeorge@hku.hk.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>11</Month>
                <Day>27</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Toxicol Sci</MedlineTA>
            <NlmUniqueID>9805461</NlmUniqueID>
            <ISSNLinking>1096-0929</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">5-lipoxygenase</Keyword>
            <Keyword MajorTopicYN="N">acute liver injury</Keyword>
            <Keyword MajorTopicYN="N">carbon tetrachloride</Keyword>
            <Keyword MajorTopicYN="N">cyclooxygenase</Keyword>
            <Keyword MajorTopicYN="N">prostaglandin</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>11</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25432964</ArticleId>
            <ArticleId IdType="pii">kfu244</ArticleId>
            <ArticleId IdType="doi">10.1093/toxsci/kfu244</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">435349</PMID>
        <DateCreated>
            <Year>1979</Year>
            <Month>07</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1979</Year>
            <Month>07</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0007-0912</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>51</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1979</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of anaesthesia</Title>
                <ISOAbbreviation>Br J Anaesth</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Suxamethonium infusion rate and observed fasciculations. A dose-response study.</ArticleTitle>
            <Pagination>
                <MedlinePgn>241-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1. The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded. Six additional patients received a 30-mg i.v. bolus dose. Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score. The times to first fasciculation, twitch suppression and tetanus suppression were inversely related to the infusion rates. Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion. Total fasciculation scores in the 30-mg bolus group and the 5-mg s-1 and 20-mg s-1 infusion groups were not significantly different.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Feingold</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Velazquez</LastName>
                    <ForeName>J L</ForeName>
                    <Initials>JL</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Br J Anaesth</MedlineTA>
            <NlmUniqueID>0372541</NlmUniqueID>
            <ISSNLinking>0007-0912</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>J2R869A8YF</RegistryNumber>
                <NameOfSubstance UI="D013390">Succinylcholine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005207">Fasciculation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007263">Infusions, Parenteral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009469">Neuromuscular Junction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013390">Succinylcholine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1979</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1979</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1979</Year>
                <Month>3</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">435349</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">20728503</PMID>
        <DateCreated>
            <Year>2010</Year>
            <Month>10</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2010</Year>
            <Month>11</Month>
            <Day>02</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-3185</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>277</Volume>
                    <Issue>1-3</Issue>
                    <PubDate>
                        <Year>2010</Year>
                        <Month>Nov</Month>
                        <Day>9</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology</Title>
                <ISOAbbreviation>Toxicology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Monocrotophos toxicity and bioenergetics of muscle weakness in the rat.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6-10</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tox.2010.08.009</ELocationID>
            <Abstract>
                <AbstractText>Acute organophosphate pesticide poisoning is a common medical emergency with high fatality in agricultural communities of Asia. Organophosphate compounds inhibit acetylcholinesterase and prolonged neuromuscular weakness is a major cause of morbidity and mortality of poisoning. Organophosphate pesticide induced muscle weakness may not only arise from inhibition of acetylcholinesterase but also from non-cholinergic pathomechanisms, particularly mitochondrial dysfunction, affecting the production of sufficient ATP for muscle function. This study examined whether muscle weakness in rats subject to monocrotophos toxicity (0.8LD₅₀) was caused by inhibition of ATP synthesis, by oxidative phosphorylation and glycolysis, in addition to inhibition of muscle acetylcholinesterase. Severe muscle weakness in rats following monocrotophos administration was associated with inhibition of muscle acetylcholinesterase (30-60%) but not with reduced ATP production. The rats rapidly recovered muscle strength with no treatment. The ability of rats to spontaneously reactivate dimethoxy phosphorylated acetylcholinesterase and efficiently detoxify organophosphates may prevent severe inhibition of muscle acetylcholinesterase following acute severe monocrotophos poisoning. This may protect rodents against the development of prolonged muscle weakness induced by organophosphates.</AbstractText>
                <CopyrightInformation>Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Raghupathy</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                    <AffiliationInfo>
                        <Affiliation>Wellcome Trust Research Laboratory, Department of Gastrointestinal Sciences, Christian Medical College, Vellore, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Poornima</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sivaguru</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramachandran</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zachariah</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oommen</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Ireland</Country>
            <MedlineTA>Toxicology</MedlineTA>
            <NlmUniqueID>0361055</NlmUniqueID>
            <ISSNLinking>0300-483X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007306">Insecticides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6923-22-4</RegistryNumber>
                <NameOfSubstance UI="D008999">Monocrotophos</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004734">Energy Metabolism</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007306">Insecticides</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008999">Monocrotophos</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018908">Muscle Weakness</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018482">Muscle, Skeletal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2010</Year>
                <Month>7</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2010</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2010</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2010</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>8</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>3</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0300-483X(10)00327-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.tox.2010.08.009</ArticleId>
            <ArticleId IdType="pubmed">20728503</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1847729</PMID>
        <DateCreated>
            <Year>1991</Year>
            <Month>04</Month>
            <Day>02</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1991</Year>
            <Month>04</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0024-3205</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>48</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>1991</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Life sciences</Title>
                <ISOAbbreviation>Life Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Modulators of N-methyl-D-aspartate protect against diazepam- or phenobarbital-resistant cocaine convulsions.</ArticleTitle>
            <Pagination>
                <MedlinePgn>PL51-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The anticonvulsants diazepam (1-10 mg/kg) and phenobarbital (30-100 mg/kg) protected against lethality without altering clonic convulsions induced by 75 mg/kg cocaine (CD100) in male Swiss Webster mice. In contrast, the non-competitive N-methyl-D-aspartate (NMDA) antagonists, MK-801 (dizocilpine) and phencyclidine, produced dose-dependent protection against cocaine convulsions. The competitive NMDA antagonists, CPP and NPC 12626, were also anti-convulsant, without producing the behavioral disturbances associated with non-competitive antagonists. Diazepam and phenobarbital protected against convulsions induced by 60 mg/kg cocaine (90% convulsions alone). Compounds that act at the strychnine-insensitive glycine receptor of the NMDA receptor complex, ACPC and 7-chlorokynurinic acid, also protected against convulsions induced by 60 mg/kg cocaine. In contrast, the non-opioid antitussive anticonvulsants (dextromethorphan, caramiphen, and carbetapentane) were not active against either dose of cocaine. The efficacy of compounds as antagonists of the convulsant effects of cocaine and NMDA appear related. These results suggest a potential role for the NMDA receptor complex in the convulsant actions of cocaine and new molecular targets for drug discovery in treating cocaine toxicity.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Witkin</LastName>
                    <ForeName>J M</ForeName>
                    <Initials>JM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Drug Development Group, Psychobiology Laboratory, NIDA Addiction Research Center, Baltimore, MD 21224.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tortella</LastName>
                    <ForeName>F C</ForeName>
                    <Initials>FC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Life Sci</MedlineTA>
            <NlmUniqueID>0375521</NlmUniqueID>
            <ISSNLinking>0024-3205</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018009">Receptors, Glycine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017981">Receptors, Neurotransmitter</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>117571-54-7</RegistryNumber>
                <NameOfSubstance UI="C060212">NPC 12626</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6LR8C1B66Q</RegistryNumber>
                <NameOfSubstance UI="D016291">Dizocilpine Maleate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I5Y540LHVR</RegistryNumber>
                <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>J1DOI7UV76</RegistryNumber>
                <NameOfSubstance UI="D010622">Phencyclidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q3JTX2Q7TU</RegistryNumber>
                <NameOfSubstance UI="D003975">Diazepam</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YQE403BP4D</RegistryNumber>
                <NameOfSubstance UI="D010634">Phenobarbital</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000596">Amino Acids</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D000927">Anticonvulsants</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003975">Diazepam</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016291">Dizocilpine Maleate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010622">Phencyclidine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010634">Phenobarbital</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018009">Receptors, Glycine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016194">Receptors, N-Methyl-D-Aspartate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017981">Receptors, Neurotransmitter</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1991</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1991</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1991</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1847729</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8588611</PMID>
        <DateCreated>
            <Year>1996</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1996</Year>
            <Month>03</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0192-9763</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>15</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>1994</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The American journal of otology</Title>
                <ISOAbbreviation>Am J Otol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Long-term results of low dose intramuscular streptomycin for Menière's disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>540-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The initial results of partial ablation of vestibular function are evident to control vertigo attacks and stabilize hearing as well as to reduce the severity of ataxia. The purpose of this study is to observe the long-term results of low dose intramuscular streptomycin in the treatment of bilateral Menière's disease. Eleven patients with disabling bilateral Menière's disease were treated with low doses of intramuscular streptomycin (20-40 g, mean = 25 g). Follow-up was 5-12 years (mean = 8 yr). All 11 patients achieved relief of their disabling vertigo. One patient had recurrent vertigo 1 year after treatment and streptomycin perfusion of the labyrinth was performed subsequently. Four patients reported feeling slightly off balance during follow-up. None experienced oscillopsia in this series. In the entire group of 11 patients (22 ears), hearing was unchanged in 17 ears, improved in two and worse in three. A hearing threshold of &lt; 30 dB was found in two ears before and two after treatment; 30-60 dB was found in seven ears before and six after treatment; and &gt; 60 dB was found in 13 ears before and 14 after treatment. The mean PTA of the 22 ears was 58 dB before and 65.5 dB after treatment. The mean speech discrimination scores were 61.4 percent before and 51.3 percent after treatment. The long-term results suggest that partial ablation of vestibular function by streptomycin has long-lasting effects of controlling vertigo attacks, stabilizing hearing, and reducing the severity of ataxia. Administration of low doses of intramuscular streptomycin is the treatment of choice for bilateral Menière's disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shea</LastName>
                    <ForeName>J J</ForeName>
                    <Initials>JJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Shea Clinic, Memphis, TN 38119, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ge</LastName>
                    <ForeName>X</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Orchik</LastName>
                    <ForeName>D J</ForeName>
                    <Initials>DJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Am J Otol</MedlineTA>
            <NlmUniqueID>7909513</NlmUniqueID>
            <ISSNLinking>0192-9763</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Y45QSO73OB</RegistryNumber>
                <NameOfSubstance UI="D013307">Streptomycin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000900">Anti-Bacterial Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001299">Audiometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001309">Auditory Threshold</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007273">Injections, Intramuscular</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008575">Meniere Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013307">Streptomycin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1994</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1994</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1994</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8588611</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18281796</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>02</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>03</Month>
            <Day>31</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2009</Year>
            <Month>11</Month>
            <Day>03</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0148-7043</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>60</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of plastic surgery</Title>
                <ISOAbbreviation>Ann Plast Surg</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Le Fort I osteotomy and the use of bilateral bichat bulla adipose flap: an effective new technique for reconstructing oronasal communications due to cocaine abuse.</ArticleTitle>
            <Pagination>
                <MedlinePgn>49-52</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1097/01.sap.0000261539.64038.a9</ELocationID>
            <Abstract>
                <AbstractText>The aim of the study was to describe a new and effective method for reconstructing small- and medium-sized oronasal communications in cases of deficient blood supply of oronasal mucosa.A male patient, aged 45, was presented with a hard palate defect due to chronic cocaine inhalation. The defect was corrected using bilateral Bichat bulla adipose flap and a Le Fort I osteotomy. The surgical technique was described, together with its advantages. Surgery lasted 2 hours. The reconstructive technique had been easy to execute. Six months after the surgery, the defect has been corrected without complications.Le Fort I osteotomy and the use of a bilateral Bichat bulla adipose flap is an effective technique to correct small- and medium-sized palatal defects not solvable with simple oral mucosa flaps. The technique is easy to execute and it showed a high efficacy with minimal impact on the patient's esthetic appearance.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pelo</LastName>
                    <ForeName>Sandro</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Unità Operativa di Chirurgia Maxillofacciale, Università Cattolica del Sacro Cuore, Rome, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gasparini</LastName>
                    <ForeName>Giulio</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Di Petrillo</LastName>
                    <ForeName>Alessandro</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tassiello</LastName>
                    <ForeName>Stefano</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Longobardi</LastName>
                    <ForeName>Gianluigi</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boniello</LastName>
                    <ForeName>Roberto</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Plast Surg</MedlineTA>
            <NlmUniqueID>7805336</NlmUniqueID>
            <ISSNLinking>0148-7043</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000273">Adipose Tissue</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009668">Nose Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016155">Oral Fistula</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D019340">Osteotomy, Le Fort</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010159">Palate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016156">Respiratory Tract Fistula</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013524">Surgical Flaps</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>2</Month>
                <Day>19</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.sap.0000261539.64038.a9</ArticleId>
            <ArticleId IdType="pii">00000637-200801000-00013</ArticleId>
            <ArticleId IdType="pubmed">18281796</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24859340</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>05</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>46</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Identification of recurrent SMO and BRAF mutations in ameloblastomas.</ArticleTitle>
            <Pagination>
                <MedlinePgn>722-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2986</ELocationID>
            <Abstract>
                <AbstractText>Here we report the discovery of oncogenic mutations in the Hedgehog and mitogen-activated protein kinase (MAPK) pathways in over 80% of ameloblastomas, locally destructive odontogenic tumors of the jaw, by genomic analysis of archival material. Mutations in SMO (encoding Smoothened, SMO) are common in ameloblastomas of the maxilla, whereas BRAF mutations are predominant in tumors of the mandible. We show that a frequently occurring SMO alteration encoding p.Leu412Phe is an activating mutation and that its effect on Hedgehog-pathway activity can be inhibited by arsenic trioxide (ATO), an anti-leukemia drug approved by the US Food and Drug Administration (FDA) that is currently in clinical trials for its Hedgehog-inhibitory activity. In a similar manner, ameloblastoma cells harboring an activating BRAF mutation encoding p.Val600Glu are sensitive to the BRAF inhibitor vemurafenib. Our findings establish a new paradigm for the diagnostic classification and treatment of ameloblastomas.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sweeney</LastName>
                    <ForeName>Robert T</ForeName>
                    <Initials>RT</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Pathology, Stanford University, Stanford, California, USA. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McClary</LastName>
                    <ForeName>Andrew C</ForeName>
                    <Initials>AC</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Pathology, Stanford University, Stanford, California, USA. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Myers</LastName>
                    <ForeName>Benjamin R</ForeName>
                    <Initials>BR</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Biochemistry, Stanford University, Stanford, California, USA. [2] Department of Developmental Biology, Stanford University, Stanford, California, USA. [3] Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA. [4] Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, California, USA. [5].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Biscocho</LastName>
                    <ForeName>Jewison</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Pathology, Stanford University, Stanford, California, USA. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Neahring</LastName>
                    <ForeName>Lila</ForeName>
                    <Initials>L</Initials>
                    <Identifier Source="ORCID">0000000322728732</Identifier>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Biochemistry, Stanford University, Stanford, California, USA. [2] Department of Developmental Biology, Stanford University, Stanford, California, USA. [3] Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA. [4] Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kwei</LastName>
                    <ForeName>Kevin A</ForeName>
                    <Initials>KA</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Genomic Health, Redwood City, California, USA. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qu</LastName>
                    <ForeName>Kunbin</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genomic Health, Redwood City, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gong</LastName>
                    <ForeName>Xue</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Stanford University, Stanford, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ng</LastName>
                    <ForeName>Tony</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jones</LastName>
                    <ForeName>Carol D</ForeName>
                    <Initials>CD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Stanford University, Stanford, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Varma</LastName>
                    <ForeName>Sushama</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Stanford University, Stanford, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Odegaard</LastName>
                    <ForeName>Justin I</ForeName>
                    <Initials>JI</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Stanford University, Stanford, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sugiyama</LastName>
                    <ForeName>Toshihiro</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Akita University Graduate School of Medicine, Akita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koyota</LastName>
                    <ForeName>Souichi</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry, Akita University Graduate School of Medicine, Akita, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rubin</LastName>
                    <ForeName>Brian P</ForeName>
                    <Initials>BP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Troxell</LastName>
                    <ForeName>Megan L</ForeName>
                    <Initials>ML</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Oregon Health and Sciences University, Portland, Oregon, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pelham</LastName>
                    <ForeName>Robert J</ForeName>
                    <Initials>RJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Genomic Health, Redwood City, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zehnder</LastName>
                    <ForeName>James L</ForeName>
                    <Initials>JL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Stanford University, Stanford, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beachy</LastName>
                    <ForeName>Philip A</ForeName>
                    <Initials>PA</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Biochemistry, Stanford University, Stanford, California, USA. [2] Department of Developmental Biology, Stanford University, Stanford, California, USA. [3] Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA. [4] Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pollack</LastName>
                    <ForeName>Jonathan R</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Stanford University, Stanford, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>West</LastName>
                    <ForeName>Robert B</ForeName>
                    <Initials>RB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Stanford University, Stanford, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>dbGaP</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>PHS000739.V1.P1</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P30 CA124435</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <Agency>Howard Hughes Medical Institute</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>05</Month>
                <Day>25</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001152">Arsenicals</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010087">Oxides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C551177">PLX4032</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C491023">SMO protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>1327-53-3</RegistryNumber>
                <NameOfSubstance UI="C006632">arsenic trioxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="C482119">BRAF protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Biol. 1999 Jan 1;205(1):1-9</RefSource>
                <PMID Version="1">9882493</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Oral Pathol Med. 1998 May;27(5):207-12</RefSource>
                <PMID Version="1">9682983</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Transl Med. 2010;8:39</RefSource>
                <PMID Version="1">20406486</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2010 Mar 15;26(6):730-6</RefSource>
                <PMID Version="1">20130035</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Biol. 2009 Feb 10;19(3):R132-42</RefSource>
                <PMID Version="1">19211055</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13432-7</RefSource>
                <PMID Version="1">20624968</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2010 Sep;38(16):e164</RefSource>
                <PMID Version="1">20601685</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Comput Biol. 2011 May;7(5):e1001138</RefSource>
                <PMID Version="1">21625565</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 1961 Jan-Feb;14:73-101</RefSource>
                <PMID Version="1">13707265</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2011 Aug;39(15):e100</RefSource>
                <PMID Version="1">21622959</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2011 Oct 15;27(20):2903-4</RefSource>
                <PMID Version="1">21840877</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Biol. 2011;12(8):R72</RefSource>
                <PMID Version="1">21835007</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2012 Feb 1;72(3):779-89</RefSource>
                <PMID Version="1">22180495</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Methods. 2012 Apr;9(4):357-9</RefSource>
                <PMID Version="1">22388286</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Acad Dermatol. 2012 May;66(5):e167-78</RefSource>
                <PMID Version="1">20800318</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2012;7(8):e42882</RefSource>
                <PMID Version="1">22900061</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2012 Aug;40(15):e115</RefSource>
                <PMID Version="1">22730293</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2013 Jan 14;23(1):23-34</RefSource>
                <PMID Version="1">23291299</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Pathol. 2013 Mar;23(2):210-6</RefSource>
                <PMID Version="1">23432647</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2013 Mar 1;29(5):647-8</RefSource>
                <PMID Version="1">23325621</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2013 Mar 1;339(6123):1077-80</RefSource>
                <PMID Version="1">23348505</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Surg Pathol. 2013 Jun;37(6):796-803</RefSource>
                <PMID Version="1">23598961</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2013 May 16;497(7449):338-43</RefSource>
                <PMID Version="1">23636324</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Cell. 2013 Aug 26;26(4):346-57</RefSource>
                <PMID Version="1">23954590</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pathol. 2014 Apr;232(5):492-8</RefSource>
                <PMID Version="1">24374844</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2000 Aug 31;406(6799):1005-9</RefSource>
                <PMID Version="1">10984056</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Development. 2000 Nov;127(22):4775-85</RefSource>
                <PMID Version="1">11044393</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2002 Jun 27;417(6892):949-54</RefSource>
                <PMID Version="1">12068308</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Dent Res. 2002 Aug;81(8):525-30</RefSource>
                <PMID Version="1">12147741</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2003 Sep 5;308(4):834-9</RefSource>
                <PMID Version="1">12927794</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Oral Pathol Med. 2004 Mar;33(3):185-90</RefSource>
                <PMID Version="1">15128061</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Genet. 2004 Jul;5(7):499-508</RefSource>
                <PMID Version="1">15211352</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1984 Dec 13-19;312(5995):649-51</RefSource>
                <PMID Version="1">6390217</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 1997 Mar 27;14(12):1397-406</RefSource>
                <PMID Version="1">9136983</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1998 Jan 1;391(6662):90-2</RefSource>
                <PMID Version="1">9422511</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="ErratumIn">
                <RefSource>Nat Genet. 2015 Jan;47(1):97</RefSource>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000564">Ameloblastoma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001152">Arsenicals</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059014">High-Throughput Nucleotide Sequencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007573">Jaw Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010087">Oxides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016133">Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D048493">Proto-Oncogene Proteins B-raf</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D043562">Receptors, G-Protein-Coupled</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013449">Sulfonamides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014407">Tumor Cells, Cultured</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS677155 [Available on 07/01/15]</OtherID>
        <OtherID Source="NLM">PMC4418232 [Available on 07/01/15]</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>9</Month>
                <Day>5</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2986</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2986</ArticleId>
            <ArticleId IdType="pubmed">24859340</ArticleId>
            <ArticleId IdType="pmc">PMC4418232</ArticleId>
            <ArticleId IdType="mid">NIHMS677155</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21316382</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>04</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>06</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1096-0333</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>252</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Apr</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Toxicology and applied pharmacology</Title>
                <ISOAbbreviation>Toxicol. Appl. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>165-75</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.taap.2011.02.004</ELocationID>
            <Abstract>
                <AbstractText>Effective and well-tolerated anti-fibrotic drugs are currently lacking. Therefore, this study was carried out to investigate the potential anti-fibrotic effects of imatinib, nilotinib and silymarin on established hepatic fibrosis in the carbon tetrachloride (CCl(4)) rat model. Male Wistar rats received intraperitoneal injections of CCl(4) twice weekly for 8weeks, as well as daily intraperitoneal treatments of imatinib (10 and 20mg/kg), nilotinib (10 and 20mg/kg) and silymarin (100mg/kg) during the last 4weeks of CCl(4)-intoxication. At the end of the study, hepatic damage was evaluated by analysis of liver function tests and hepatic oxidative stress parameters. Hepatic fibrosis was evaluated by histopathology and morphometry, as well as collagen and 4-hydroxyproline contents. Nilotinib (20mg/kg) was the most effective treatment to counteract CCl(4)-induced hepatic injury as indicated by liver function tests and histopathology. Nilotinib (10mg/kg), nilotinib (20mg/kg) and silymarin (100mg/kg) treatments reduced the mean score of hepatic fibrosis by 31%, 68% and 47%, respectively, and hepatic collagen content by 47%, 49% and 18%, respectively in CCl(4)-treated rats. Hepatic morphometric evaluation and 4-hydroxyproline content revealed that CCl(4)-induced fibrosis was ameliorated significantly by nilotinib (20mg/kg) and imatinib (20mg/kg). Unlike nilotinib, imatinib (20mg/kg) showed some sort of hepatic injury evidenced by elevation of serum aminotransferases and total bilirubin levels, and hepatic total nitrate/nitrite content, as well as characteristic anisonucleosis visualized with the hematoxylin-eosin staining. In conclusion, this study provides the evidence that nilotinib exerts anti-fibrotic activity and suggests that it may be valuable in the treatment of hepatic fibrosis in humans.</AbstractText>
                <CopyrightInformation>Copyright © 2011 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Shaker</LastName>
                    <ForeName>Mohamed E</ForeName>
                    <Initials>ME</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt. mshaker2222@yahoo.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zalata</LastName>
                    <ForeName>Khaled R</ForeName>
                    <Initials>KR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mehal</LastName>
                    <ForeName>Wajahat Z</ForeName>
                    <Initials>WZ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shiha</LastName>
                    <ForeName>Gamal E</ForeName>
                    <Initials>GE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ibrahim</LastName>
                    <ForeName>Tarek M</ForeName>
                    <Initials>TM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>R01 DK076674</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 DK076674-04</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>02</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Toxicol Appl Pharmacol</MedlineTA>
            <NlmUniqueID>0416575</NlmUniqueID>
            <ISSNLinking>0041-008X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C498826">4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012838">Silymarin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>BKJ8M8G5HI</RegistryNumber>
                <NameOfSubstance UI="C097613">imatinib</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dig Dis Sci. 2007 Feb;52(2):598-601</RefSource>
                <PMID Version="1">17219077</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2007 Jan;56(1):311-22</RefSource>
                <PMID Version="1">17195235</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Haematol. 2007;118(4):205-8</RefSource>
                <PMID Version="1">18030002</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Free Radic Biol Med. 2008 Mar 1;44(5):868-81</RefSource>
                <PMID Version="1">18160052</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Gastroenterology. 2008 May;134(6):1655-69</RefSource>
                <PMID Version="1">18471545</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FASEB J. 2008 Jul;22(7):2214-22</RefSource>
                <PMID Version="1">18326784</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v10-1</RefSource>
                <PMID Version="1">18784126</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicology. 2008 Dec 30;254(3):120-9</RefSource>
                <PMID Version="1">18662740</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioorg Med Chem. 2010 Oct 1;18(19):6977-86</RefSource>
                <PMID Version="1">20817538</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fundam Clin Pharmacol. 2011 Apr;25(2):248-57</RefSource>
                <PMID Version="1">20408881</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Pharmacol. 2008 Dec 3;599(1-3):44-53</RefSource>
                <PMID Version="1">18938156</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Kidney Dis. 2009 Jan;53(1):129-32</RefSource>
                <PMID Version="1">19012999</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Ther. 2008 Nov;30(11):1956-75</RefSource>
                <PMID Version="1">19108785</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Rheumatol. 2009 Jun;5(6):317-24</RefSource>
                <PMID Version="1">19491913</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S10-9</RefSource>
                <PMID Version="1">19555853</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Physiol Biochem. 2009 Sep;65(3):225-33</RefSource>
                <PMID Version="1">20119817</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2000 Jun 9;275(23):17237-40</RefSource>
                <PMID Version="1">10770918</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2000 Nov 20;19(49):5548-57</RefSource>
                <PMID Version="1">11114734</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nitric Oxide. 2001 Feb;5(1):62-71</RefSource>
                <PMID Version="1">11178938</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2001 May 18;276(20):17281-5</RefSource>
                <PMID Version="1">11350980</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Z Naturforsch C. 2001 Jul-Aug;56(7-8):649-59</RefSource>
                <PMID Version="1">11531102</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2002 May;8(5):935-42</RefSource>
                <PMID Version="1">12006504</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Front Biosci. 2003 Jan 1;8:d69-77</RefSource>
                <PMID Version="1">12456323</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 2003 Feb;63(2):276-82</RefSource>
                <PMID Version="1">12527798</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Crit Rev Toxicol. 2003;33(2):105-36</RefSource>
                <PMID Version="1">12708612</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2003 Jun;9(6):1972-9</RefSource>
                <PMID Version="1">12796358</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2003 Oct 10;278(41):39609-14</RefSource>
                <PMID Version="1">12893824</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2004 Mar 1;22(5):935-42</RefSource>
                <PMID Version="1">14990650</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Biochem. 1974 Sep 16;47(3):469-74</RefSource>
                <PMID Version="1">4215654</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochim Biophys Acta. 1979 Jan 4;582(1):67-78</RefSource>
                <PMID Version="1">760819</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anal Biochem. 1983 Mar;129(2):483-5</RefSource>
                <PMID Version="1">6846843</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 1986 Nov;69:301-5</RefSource>
                <PMID Version="1">3816733</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Histochem Cytochem. 1989 Mar;37(3):377-81</RefSource>
                <PMID Version="1">2465335</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Methods. 1990 May;23(3):179-86</RefSource>
                <PMID Version="1">2158602</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1993 Apr;119(2):275-9</RefSource>
                <PMID Version="1">8480336</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1995 Mar 24;267(5205):1782-8</RefSource>
                <PMID Version="1">7892601</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Hepatol. 1995 Jun;22(6):696-9</RefSource>
                <PMID Version="1">7560864</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Chem Res Toxicol. 1998 Oct;11(10):1176-83</RefSource>
                <PMID Version="1">9778314</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2004 Nov;114(9):1308-16</RefSource>
                <PMID Version="1">15520863</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FASEB J. 2005 Jan;19(1):1-11</RefSource>
                <PMID Version="1">15629889</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G907-13</RefSource>
                <PMID Version="1">15618280</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Respir Crit Care Med. 2005 Jun 1;171(11):1279-85</RefSource>
                <PMID Version="1">15735062</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Gastroenterol Hepatol. 2005 Jul;20(7):1109-14</RefSource>
                <PMID Version="1">15955222</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2005 Jul 14;353(2):172-87</RefSource>
                <PMID Version="1">16014887</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13622-7</RefSource>
                <PMID Version="1">16174751</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Hepatol. 2006 Jan;44(1):167-75</RefSource>
                <PMID Version="1">16168515</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Mol Med. 2006 May;17(5):899-904</RefSource>
                <PMID Version="1">16596278</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharm Pharmacol. 2006 Apr;58(4):567-73</RefSource>
                <PMID Version="1">16597375</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Clin Invest. 2006 Apr;36(4):242-9</RefSource>
                <PMID Version="1">16620286</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Gastroenterol Hepatol. 2006 Jun;21(6):947-57</RefSource>
                <PMID Version="1">16724977</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Pharmacol Exp Ther. 2007 Apr;321(1):35-44</RefSource>
                <PMID Version="1">17218487</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001549">Benzamides</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002252">Carbon Tetrachloride Poisoning</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056486">Drug-Induced Liver Injury</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008103">Liver Cirrhosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018384">Oxidative Stress</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010879">Piperazines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011743">Pyrimidines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012838">Silymarin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS335050</OtherID>
        <OtherID Source="NLM">PMC3895503</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2010</Year>
                <Month>11</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2011</Year>
                <Month>2</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2011</Year>
                <Month>2</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2011</Year>
                <Month>2</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>2</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>2</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>6</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0041-008X(11)00050-0</ArticleId>
            <ArticleId IdType="doi">10.1016/j.taap.2011.02.004</ArticleId>
            <ArticleId IdType="pubmed">21316382</ArticleId>
            <ArticleId IdType="pmc">PMC3895503</ArticleId>
            <ArticleId IdType="mid">NIHMS335050</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16362348</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>02</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>04</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2008</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0340-6717</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>119</Volume>
                    <Issue>1-2</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Human genetics</Title>
                <ISOAbbreviation>Hum. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Functional polymorphisms of FGA, encoding alpha fibrinogen, are associated with susceptibility to venous thromboembolism in a Taiwanese population.</ArticleTitle>
            <Pagination>
                <MedlinePgn>84-91</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>To determine the genetic risk factors for venous thromboembolism (VTE), this study examined 14 genetic variants from 10 hemostatic genes in 186 Taiwanese VTE patients and the same number of matched controls, which demonstrated FGA (encoding alpha fibrinogen) Thr312Ala polymorphism was the only variant significantly associated with VTE. Nine genetic polymorphisms on the fibrinogen cluster region of chromosome 4q28 were further studied, in which four FGA polymorphisms were found in strong linkage disequilibrium and were significantly associated with VTE by genotype and allele frequency analyses. Haplotype analysis showed significantly different FGA haplotype frequencies between VTE patients and controls with the haplotype F1, containing -1051G, -3A, 312Ala and TaqI duplication alleles, significantly associated with susceptibility to VTE (P = 0.001). Haplotype-pair analysis results also indicated a strong association of the haplotype-pair F1F1 with VTE in various VTE patient subgroups. In vitro functional analysis indicated that FGA -1051G, -3A and TaqI duplication alleles enhanced significantly the transcription level of FGA; however, control subjects with FGA genotypes containing these alleles had no elevated plasma fibrinogen levels. In conclusion, our experimental data indicated that functional genetic variants in FGA are risk factors for VTE in Taiwanese populations. Determination of FGA genotypes will likely contribute to primary prevention of this condition.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ko</LastName>
                    <ForeName>Yu-Lin</ForeName>
                    <Initials>YL</Initials>
                    <AffiliationInfo>
                        <Affiliation>The First Cardiovascular Division, Chang-Gung Memorial Hospital, No. 199, Tung-Hwa North Road, Taipei, Taiwan, ROC. yulinkotw@yahoo.com.tw</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsu</LastName>
                    <ForeName>Lung-An</ForeName>
                    <Initials>LA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hsu</LastName>
                    <ForeName>Tsu-Shiu</ForeName>
                    <Initials>TS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsai</LastName>
                    <ForeName>Chia-Ti</ForeName>
                    <Initials>CT</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teng</LastName>
                    <ForeName>Ming-Sheng</ForeName>
                    <Initials>MS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Semon</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Chi-Jen</ForeName>
                    <Initials>CJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Ying-Shiung</ForeName>
                    <Initials>YS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2005</Year>
                <Month>12</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Hum Genet</MedlineTA>
            <NlmUniqueID>7613873</NlmUniqueID>
            <ISSNLinking>0340-6717</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9001-32-5</RegistryNumber>
                <NameOfSubstance UI="D005340">Fibrinogen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.13.12.-</RegistryNumber>
                <NameOfSubstance UI="D008156">Luciferases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000483">Alleles</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004252">DNA Mutational Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005340">Fibrinogen</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015870">Gene Expression</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005787">Gene Frequency</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005838">Genotype</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006239">Haplotypes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008156">Luciferases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011110">Polymorphism, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018807">Polymorphism, Single-Stranded Conformational</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D021122">Protein Subunits</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011993">Recombinant Fusion Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D013624">Taiwan</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013923">Thromboembolism</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020246">Venous Thrombosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2005</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2005</Year>
                <Month>11</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2005</Year>
                <Month>12</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>12</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>4</Month>
                <Day>3</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>12</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00439-005-0102-0</ArticleId>
            <ArticleId IdType="pubmed">16362348</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">14686790</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>12</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>02</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1052-2166</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <Issue>3-4</Issue>
                    <PubDate>
                        <Year>2003</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Gene expression</Title>
                <ISOAbbreviation>Gene Expr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Gene expression profiling of the hypoxia signaling pathway in hypoxia-inducible factor 1alpha null mouse embryonic fibroblasts.</ArticleTitle>
            <Pagination>
                <MedlinePgn>181-97</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Hypoxia is defined as a deficiency of oxygen reaching the tissues of the body, and it plays a critical role in development and pathological conditions, such as cancer. Once tumors outgrow their blood supply, their central portion becomes hypoxic and the tumor stimulates angiogenesis through the activation of the hypoxia-inducible factors (HIFs). HIFs are transcription factors that are regulated in an oxygen-dependent manner by a group of prolyl hydroxylases (known as PHDs or HPHs). Our understanding of hypoxia signaling is limited by our incomplete knowledge of HIF target genes. cDNA microarrays and a cell line lacking a principal HIF protein, HIF1alpha, were used to identify a more complete set of hypoxia-regulated genes. The microarrays identified a group of 286 clones that were significantly influenced by hypoxia and 54 of these were coordinately regulated by cobalt chloride. The expression profile of HIF1alpha -/- cells also identified a group of downregulated genes encoding enzymes involved in protecting cells from oxidative stress, offering an explanation for the increased sensitivity of HIF1alpha -/- cells to agents that promote this type of response. The microarray studies confirmed the hypoxia-induced expression of the HIF regulating prolyl hydroxylase, PHD2. An analysis of the members of the PHD family revealed that they are differentially regulated by cobalt chloride and hypoxia. These results suggest that HIF1alpha is the predominant isoform in fibroblasts and that it regulates a wide battery of genes critical for normal cellular function and survival under various stresses.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Vengellur</LastName>
                    <ForeName>Ajith</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Molecular Biology, The National Food Safety and Toxicology Center, Michigan State University, East Lansing, MI 48824, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Woods</LastName>
                    <ForeName>Barbara G</ForeName>
                    <Initials>BG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ryan</LastName>
                    <ForeName>Heather E</ForeName>
                    <Initials>HE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johnson</LastName>
                    <ForeName>Randall S</ForeName>
                    <Initials>RS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>LaPres</LastName>
                    <ForeName>John J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Gene Expr</MedlineTA>
            <NlmUniqueID>9200651</NlmUniqueID>
            <ISSNLinking>1052-2166</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3G0H8C9362</RegistryNumber>
                <NameOfSubstance UI="D003035">Cobalt</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7646-79-9</RegistryNumber>
                <NameOfSubstance UI="C018021">cobaltous chloride</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.11.2</RegistryNumber>
                <NameOfSubstance UI="D011393">Procollagen-Proline Dioxygenase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S88TT14065</RegistryNumber>
                <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015687">Cell Hypoxia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002478">Cells, Cultured</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003035">Cobalt</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005347">Fibroblasts</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020869">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051795">Hypoxia-Inducible Factor 1, alpha Subunit</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018345">Mice, Knockout</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010100">Oxygen</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011393">Procollagen-Proline Dioxygenase</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014157">Transcription Factors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014158">Transcription, Genetic</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>12</Month>
                <Day>23</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>2</Month>
                <Day>3</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>12</Month>
                <Day>23</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">14686790</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19473592</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>06</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0946-1965</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>47</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>International journal of clinical pharmacology and therapeutics</Title>
                <ISOAbbreviation>Int J Clin Pharmacol Ther</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review.</ArticleTitle>
            <Pagination>
                <MedlinePgn>303-10</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Ciprofloxacin-associated seizures (CAS) occur most commonly in patients with special risk factors that may cause accumulation of drug (high doses of the drug, old age, renal insufficiency, drug interactions) or that may decrease the threshold of epileptogenic activity (electrolyte abnormalities, history of seizures, electroconvulsive therapy).</AbstractText>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To report thyrotoxicosis as a risk factor previously not heralded for the development of CAS.</AbstractText>
                <AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 24-year-old woman was admitted to the hospital because of convulsions, severe myopathy, and acute renal failure after taking ciprofloxacin for sinusitis, and urinary tract infections. Prior to ciprofloxacin ingestion, she had no seizure history, was not receiving any other medication, and her routine laboratory results including creatinine and electrolytes were within normal ranges. Electroencephalogram suggested epileptiform waves. Cranial magnetic resonance imaging was normal. Further laboratory examinations documented thyrotoxicosis in association with postpartum thyroiditis.</AbstractText>
                <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">In the reviewed literature, all cases of CAS occurred in the presence of at least one risk factor for CAS.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CAS appear to be restricted to individuals with predisposing risk factors, therefore it is always necessary to search such fact. When a physician encounters the possibility of CAS, in addition to previously described risk factors, thyrotoxicosis should also be considered in the differential diagnosis. Further, in patients with untreated thyrotoxicosis, antibiotics other than ciprofloxacin might be preferable for therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Agbaht</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Internal Medicine, Endocrinology and Metabolism Unit, Ankara University Faculty of Medicine, Sihhiye, Ankara, Turkey. dr_kemal@yahoo.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bitik</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Piskinpasa</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bayraktar</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Topeli</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Int J Clin Pharmacol Ther</MedlineTA>
            <NlmUniqueID>9423309</NlmUniqueID>
            <ISSNLinking>0946-1965</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5E8K9I0O4U</RegistryNumber>
                <NameOfSubstance UI="D002939">Ciprofloxacin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000890">Anti-Infective Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002939">Ciprofloxacin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004569">Electroencephalography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012852">Sinusitis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013971">Thyrotoxicosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014552">Urinary Tract Infections</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>34</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">5977</ArticleId>
            <ArticleId IdType="pubmed">19473592</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19424620</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>07</Month>
            <Day>09</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1021-335X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>21</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Oncology reports</Title>
                <ISOAbbreviation>Oncol. Rep.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Two-dimensional differential in-gel electrophoresis for identification of gastric cancer-specific protein markers.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1429-37</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Gastric cancer is the second most common fatal malignancy in the world. Proteomics studies of clinical tumor samples have led to the identification of specific protein markers of gastric cancer detection and better understanding the carcinogenesis of gastric cancer. Gastric cancer tissue of epithelial origin and adjacent normal mucosa were examined in pair by fluorescence 2-D differential in-gel electrophoresis proteomics analysis utilizing 2-D PAGE protein separation. Intensity changes of 33 spots were detected with statistical significance. Twenty-two out of the 33 spots were identified by MALDI-TOF MS or MS/MS. Of the 9 up-regulated proteins, 7 were identified, including heat shock protein 60 (HSP60), mutant desmin, effector cell proteinase receptor 1 splice form 1b, hypothetical protein, unnamed protein product, and manganese superoxide dismutase (MnSOD), a protein similar to alpha-actin. Of the 20 down-regulated proteins, 16 were identified, including selenium binding protein 1, fibrinogen gamma, HSP27, tubulin alpha 6, zinc finger protein 160, prostaglandin F synthase, and eukaryotic translation elongation factor 1 alpha 1. Our results suggest that MnSOD may be a potential serum marker for molecular diagnosis of gastric carcinoma, and DIGE is a useful technique for screening differentially expressed proteins in cancer tissues.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Cheng</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Luo</LastName>
                    <ForeName>Zhiwen</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Xueyun</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Chaoqun</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yao</LastName>
                    <ForeName>Dingkang</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Peng</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Lijie</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Liang</ForeName>
                    <Initials>L</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Greece</Country>
            <MedlineTA>Oncol Rep</MedlineTA>
            <NlmUniqueID>9422756</NlmUniqueID>
            <ISSNLinking>1021-335X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002232">Carbocyanines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009363">Neoplasm Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014408">Tumor Markers, Biological</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C089187">cyanine dye 3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C085321">cyanine dye 5</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001706">Biopsy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002232">Carbocyanines</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D015180">Electrophoresis, Gel, Two-Dimensional</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005456">Fluorescent Dyes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009363">Neoplasm Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009367">Neoplasm Staging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D040901">Proteomics</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013050">Spectrometry, Fluorescence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019032">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013274">Stomach Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053719">Tandem Mass Spectrometry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014408">Tumor Markers, Biological</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>5</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>7</Month>
                <Day>10</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">19424620</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24120900</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>26</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>15</Day>
        </DateCompleted>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-6351</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>62</Volume>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association</Title>
                <ISOAbbreviation>Food Chem. Toxicol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy of PLGA-loaded apigenin nanoparticles in Benzo[a]pyrene and ultraviolet-B induced skin cancer of mice: mitochondria mediated apoptotic signalling cascades.</ArticleTitle>
            <Pagination>
                <MedlinePgn>670-80</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.fct.2013.09.037</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0278-6915(13)00675-3</ELocationID>
            <Abstract>
                <AbstractText>Skin cancer is increasing at an alarming rate and becoming resistant to conventional chemotherapy necessitating improved drug delivery system. We loaded apigenin (Ap), a dietary flavonoid having anti-cancer property, with poly (lactic-co-glycolide) (PLGA) nanoparticles (NAp) to explore if nano-encapsulation could enhance anti-carcinogenic effect against ultra-violet B (UVB) and Benzo(a)pyrene (BaP) induced skin tumor and mitochondrial dysfunction in mice. Particle size, morphology and zeta potential of NAp were determined using dynamic light scattering and atomic force microscopy. Tumor incidence and multiplicity in UVB-BaP induced mice with/without NAp treatment were ascertained and their histolopathological sections and chromosomal aberrations were studied. ROS accumulation and mitochondrial functioning through relevant markers like mitochondrial transmembrane potential were analyzed. Mitochondrial volume changes/swelling, cytochrome c (cyt c) release, mRNA and protein expressions of Apaf-1, bax, bcl-2, cyt c, cleaved caspase-9 and 3 were studied. Results showed that NAp produced better effects than Ap, due to their smaller size, and faster mobility. NAp reduced tissue damage and frequency of chromosomal aberrations, increased ROS accumulation to mediate mitochondrial-apoptosis through modulation of several apoptotic markers and mitochondrial matrix swelling. NAp showed ameliorative potentials in combating skin cancer and therefore has greater prospect of use in therapeutic management of skin cancer.</AbstractText>
                <CopyrightInformation>Copyright © 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Das</LastName>
                    <ForeName>Sreemanti</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cytogenetics and Molecular Biology Laboratory, Department of Zoology, University of Kalyani, Kalyani 741235, West Bengal, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Das</LastName>
                    <ForeName>Jayeeta</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Samadder</LastName>
                    <ForeName>Asmita</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Paul</LastName>
                    <ForeName>Avijit</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Khuda-Bukhsh</LastName>
                    <ForeName>Anisur Rahman</ForeName>
                    <Initials>AR</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>09</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Food Chem Toxicol</MedlineTA>
            <NlmUniqueID>8207483</NlmUniqueID>
            <ISSNLinking>0278-6915</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016588">Anticarcinogenic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C043435">polylactic acid-polyglycolic acid copolymer</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>26009-03-0</RegistryNumber>
                <NameOfSubstance UI="D011100">Polyglycolic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>33X04XA5AT</RegistryNumber>
                <NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3417WMA06D</RegistryNumber>
                <NameOfSubstance UI="D001564">Benzo(a)pyrene</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7V515PI7F6</RegistryNumber>
                <NameOfSubstance UI="D047310">Apigenin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016588">Anticarcinogenic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D047310">Apigenin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001564">Benzo(a)pyrene</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004337">Drug Carriers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019344">Lactic Acid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053078">Membrane Potential, Mitochondrial</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008928">Mitochondria</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053758">Nanoparticles</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009381">Neoplasms, Radiation-Induced</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011100">Polyglycolic Acid</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017382">Reactive Oxygen Species</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014466">Ultraviolet Rays</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Apigenin</Keyword>
            <Keyword MajorTopicYN="N">Apoptosis</Keyword>
            <Keyword MajorTopicYN="N">Benzo[a]pyrene</Keyword>
            <Keyword MajorTopicYN="N">PLGA-nano-encapsulation</Keyword>
            <Keyword MajorTopicYN="N">Ultra-violet-B</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>9</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>16</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">24120900</ArticleId>
            <ArticleId IdType="pii">S0278-6915(13)00675-3</ArticleId>
            <ArticleId IdType="doi">10.1016/j.fct.2013.09.037</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10562259</PMID>
        <DateCreated>
            <Year>1999</Year>
            <Month>12</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1999</Year>
            <Month>12</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2007</Year>
            <Month>11</Month>
            <Day>15</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1524-4539</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>100</Volume>
                    <Issue>20</Issue>
                    <PubDate>
                        <Year>1999</Year>
                        <Month>Nov</Month>
                        <Day>16</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Circulation</Title>
                <ISOAbbreviation>Circulation</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clinical outcomes of bivalirudin for ischemic heart disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>2049-53</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Current treatment strategies for percutaneous coronary revascularization and acute coronary syndromes incorporate thrombin inhibition with either unfractionated or fractionated heparin. The peptide bivalirudin (Hirulog) is a direct thrombin inhibitor whose pharmacological properties differ from those of heparin. We conducted a systematic overview (meta-analysis) to assess the effect of bivalirudin on 4 end points: death, myocardial infarction, major hemorrhage, and the composite of death or infarction.</AbstractText>
                <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Six trials (5674 patients) represent the randomized, controlled bivalirudin experience, including 4603 patients undergoing elective percutaneous coronary revascularization and 1071 patients with acute coronary syndromes. ORs for the 4 clinical end points were calculated for each trial. Four trials (4973 patients) that compared bivalirudin with heparin were combined with the use of a random-effects model. In these trials, bivalirudin was associated with a significant reduction in the composite of death or infarction (OR 0.73, 95% CI 0.57 to 0.95; P=0.02) at 30 to 50 days, or 14 fewer events per 1000 patients so treated. There also was a significant reduction in major hemorrhage for the same trials (OR 0.41, 95% CI 0. 32 to 0.52; P&lt;0.001, or 58 fewer events per 1000 patients so treated). A similar analysis combined 2 dose-ranging trials (701 patients) that compared therapeutic (activated partial thromboplastin time more than twice the control time) with subtherapeutic bivalirudin anticoagulation (activated partial thromboplastin time less than twice the control time).</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bivalirudin is at least as effective as heparin, with clearly superior safety. Thus, it provides an unprecedented net clinical benefit over heparin in patients with ischemic heart disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kong</LastName>
                    <ForeName>D F</ForeName>
                    <Initials>DF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Duke Clinical Research Institute, Durham, NC 27715, USA. kong0008@mc.duke.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Topol</LastName>
                    <ForeName>E J</ForeName>
                    <Initials>EJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bittl</LastName>
                    <ForeName>J A</ForeName>
                    <Initials>JA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>White</LastName>
                    <ForeName>H D</ForeName>
                    <Initials>HD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Théroux</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hasselblad</LastName>
                    <ForeName>V</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Califf</LastName>
                    <ForeName>R M</ForeName>
                    <Initials>RM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D017418">Meta-Analysis</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Circulation</MedlineTA>
            <NlmUniqueID>0147763</NlmUniqueID>
            <ISSNLinking>0009-7322</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015415">Biological Markers</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006629">Hirudins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>128270-60-0</RegistryNumber>
                <NameOfSubstance UI="C074619">bivalirudin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9005-49-6</RegistryNumber>
                <NameOfSubstance UI="D006493">Heparin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000925">Anticoagulants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015415">Biological Markers</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006493">Heparin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D024764">Hirudin Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006629">Hirudins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017202">Myocardial Ischemia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017063">Outcome Assessment (Health Care)</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010446">Peptide Fragments</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016032">Randomized Controlled Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011994">Recombinant Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1999</Year>
                <Month>11</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1999</Year>
                <Month>11</Month>
                <Day>16</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1999</Year>
                <Month>11</Month>
                <Day>16</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10562259</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">4142233</PMID>
        <DateCreated>
            <Year>1975</Year>
            <Month>07</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1975</Year>
            <Month>07</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0070-4113</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>57</Volume>
                    <PubDate>
                        <Year>1973</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Verhandlungen der Deutschen Gesellschaft für Pathologie</Title>
                <ISOAbbreviation>Verh Dtsch Ges Pathol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Proceedings: Renin secretion and juxtaglomerular apparatus in folic-acid-induced kidney failure in the rat].</ArticleTitle>
            <Pagination>
                <MedlinePgn>393</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Helmchen</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kirchertz</LastName>
                    <ForeName>E J</ForeName>
                    <Initials>EJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kneissler</LastName>
                    <ForeName>U</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Reifferscheid</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>ger</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Reninsekretion und juxtaglomerulärer Apparat beim Folsäure-induzierten akuten Nierenversagen der Ratte</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>GERMANY, WEST</Country>
            <MedlineTA>Verh Dtsch Ges Pathol</MedlineTA>
            <NlmUniqueID>7503704</NlmUniqueID>
            <ISSNLinking>0070-4113</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>935E97BOY8</RegistryNumber>
                <NameOfSubstance UI="D005492">Folic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.23.15</RegistryNumber>
                <NameOfSubstance UI="D012083">Renin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D058186">Acute Kidney Injury</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005492">Folic Acid</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007606">Juxtaglomerular Apparatus</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012083">Renin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1973</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1973</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1973</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">4142233</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10914763</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>11</Month>
            <Day>03</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0004-8291</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>30</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2000</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Australian and New Zealand journal of medicine</Title>
                <ISOAbbreviation>Aust N Z J Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cerebrospinal fluid (CSF) rhinorrhoea occurring six days after commencement of bromocriptine for invasive macroprolactinoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>399-400</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hewage</LastName>
                    <ForeName>U C</ForeName>
                    <Initials>UC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Colman</LastName>
                    <ForeName>P G</ForeName>
                    <Initials>PG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kaye</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>AUSTRALIA</Country>
            <MedlineTA>Aust N Z J Med</MedlineTA>
            <NlmUniqueID>1264322</NlmUniqueID>
            <ISSNLinking>0004-8291</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>3A64E3G5ZO</RegistryNumber>
                <NameOfSubstance UI="D001971">Bromocriptine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001971">Bromocriptine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002559">Cerebrospinal Fluid Rhinorrhea</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010911">Pituitary Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015175">Prolactinoma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>7</Month>
                <Day>29</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>2</Month>
                <Day>28</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>7</Month>
                <Day>29</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10914763</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">22609695</PMID>
        <DateCreated>
            <Year>2012</Year>
            <Month>10</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>03</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>10</Month>
            <Day>16</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-9711</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>33</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2012</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Neurotoxicology</Title>
                <ISOAbbreviation>Neurotoxicology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Developmental lead effects on behavior and brain gene expression in male and female BALB/cAnNTac mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1005-20</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuro.2012.04.017</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">S0161-813X(12)00093-9</ELocationID>
            <Abstract>
                <AbstractText>Lead (Pb) was one of the first poisons identified, and the developing nervous system is particularly vulnerable to its toxic effects. Relatively low, subclinical doses, of Pb that produce no overt signs of encephalopathy can affect cognitive, emotional, and motor functions. In the present study, the effects of developmental Pb-exposure on behavioral performance and gene expression in BALB/cAnNTac mice were evaluated. Pups were exposed to Pb from gestational-day (gd) 8 to postnatal-day (pnd) 21 and later evaluated in exploratory behavior, rotarod, Morris water maze, and resident-intruder assays as adults. Pb-exposure caused significant alterations in exploratory behavior and water maze performance during the probe trial, but rotarod performance was not affected. Pb-exposed males displayed violent behavior towards their cage mates, but not to a stranger in the resident-intruder assay. Gene expression analysis at pnd21 by microarray and qRT-PCR was performed to provide a molecular link to the behavior changes that were observed. Pb strongly up-regulated gene expression within the signaling pathways of mitogen activated protein kinases (MAPKs), extra-cellular matrix (ECM) receptor, focal adhesion, and vascular endothelial growth-factor (VEGF), but Pb down-regulated gene expression within the pathways for glycan structures-biosynthesis 1, purine metabolism, and N-glycan biosynthesis. Pb increased transcription of genes for major histocompatibility (MHC) proteins, the chemokine Ccl28, chemokine receptors, IL-7, IL7R, and proteases. The qRT-PCR analysis indicated an increase of gene expression in the whole brain for caspase 1 and NOS2. Analysis of IL-1β, caspase 1, NOS2, Trail, IL-18 and IL-33 gene expression of brain regions indicated that Pb perturbed the inter-regional expression pattern of pro-inflammatory genes. Brain region protein concentrations for IL-10, an anti-inflammatory cytokine, showed a significant decrease only within the cortex region. Results indicate that Pb differentially affects the behavior of male and female mice in that females did less exploration and the males were selectively more aggressive. Gene expression data pointed to evidence of neuroinflammation in the brain of both female and male mice. Pb had more of an effect in the males on expression of vomeronasal receptor genes associated with odor detection and social behavior.</AbstractText>
                <CopyrightInformation>Copyright © 2012 Elsevier Inc. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kasten-Jolly</LastName>
                    <ForeName>Jane</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>New York State Department of Health, Wadsworth Center, Albany, NY 12208, USA. kjolly@wadsworth.org</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pabello</LastName>
                    <ForeName>Nina</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bolivar</LastName>
                    <ForeName>Valerie J</ForeName>
                    <Initials>VJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lawrence</LastName>
                    <ForeName>David A</ForeName>
                    <Initials>DA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>ES011135</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>ES013857</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 ES011135</GrantID>
                    <Acronym>ES</Acronym>
                    <Agency>NIEHS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>05</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Neurotoxicology</MedlineTA>
            <NlmUniqueID>7905589</NlmUniqueID>
            <ISSNLinking>0161-813X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D042442">Vascular Endothelial Growth Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C052131">extracellular matrix receptor</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>2P299V784P</RegistryNumber>
                <NameOfSubstance UI="D007854">Lead</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2007 Nov 15;225(1):1-27</RefSource>
                <PMID Version="1">17904601</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicology. 2007 Nov;28(6):1170-7</RefSource>
                <PMID Version="1">17868887</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Neurosci. 2007 Dec;26(12):3382-94</RefSource>
                <PMID Version="1">18052982</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2008 Apr 25;320(5875):535-8</RefSource>
                <PMID Version="1">18436787</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Med. 2008 May 27;5(5):e101</RefSource>
                <PMID Version="1">18507497</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Med. 2008 May 27;5(5):e115</RefSource>
                <PMID Version="1">18507501</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurosci Biobehav Rev. 2008 Aug;32(6):1136-51</RefSource>
                <PMID Version="1">18468686</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Ther. 2008;30 Spec No:1017-24</RefSource>
                <PMID Version="1">18640476</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Leukoc Biol. 2008 Sep;84(3):631-43</RefSource>
                <PMID Version="1">18552204</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Stem Cell. 2008 Sep 11;3(3):289-300</RefSource>
                <PMID Version="1">18786416</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Trop Pediatr. 2008 Oct;54(5):300-7</RefSource>
                <PMID Version="1">18353786</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurobiol Aging. 2009 Feb;30(2):198-209</RefSource>
                <PMID Version="1">17658666</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Epidemiol. 2009 Apr;19(4):235-8</RefSource>
                <PMID Version="1">19344860</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6784-9</RefSource>
                <PMID Version="1">19346486</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurobiol Learn Mem. 2009 Sep;92(2):206-14</RefSource>
                <PMID Version="1">19496240</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2009 Jul 23;114(4):816-25</RefSource>
                <PMID Version="1">19351957</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroimage. 2009 Sep;47(3):891-6</RefSource>
                <PMID Version="1">19481155</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2009 Aug;117(8):1309-12</RefSource>
                <PMID Version="1">19672413</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuron. 2009 Oct 15;64(1):40-5</RefSource>
                <PMID Version="1">19840547</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuron. 2009 Nov 25;64(4):463-70</RefSource>
                <PMID Version="1">19945389</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Neurosci. 2009 Dec;12(12):1551-8</RefSource>
                <PMID Version="1">19935653</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicology. 2009 Nov;30(6):867-75</RefSource>
                <PMID Version="1">19619581</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicology. 2009 Nov;30(6):898-914</RefSource>
                <PMID Version="1">19737576</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Dev. 2010 Mar;32(3):191-200</RefSource>
                <PMID Version="1">19232476</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurobiol Dis. 2010 Mar;37(3):574-80</RefSource>
                <PMID Version="1">19914377</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Behav Genet. 2010 Mar;40(2):201-10</RefSource>
                <PMID Version="1">20033273</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2010 Sep 1;247(2):105-15</RefSource>
                <PMID Version="1">20542052</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2010 Oct;117(2):427-38</RefSource>
                <PMID Version="1">20639260</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Behav Immun. 2010 Nov;24(8):1276-80</RefSource>
                <PMID Version="1">20685290</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Brain Behav. 2011 Feb;10(1):44-56</RefSource>
                <PMID Version="1">20618443</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biochem Mol Toxicol. 2011 Jan-Feb;25(1):41-54</RefSource>
                <PMID Version="1">21322097</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Behav Immun. 2011 Jul;25(5):820-9</RefSource>
                <PMID Version="1">20723599</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Neurobiol. 1997 Apr;7(2):157-63</RefSource>
                <PMID Version="1">9142758</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicology. 1998 Apr;19(2):283-91</RefSource>
                <PMID Version="1">9553965</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res Dev Brain Res. 1998 May 15;107(2):291-8</RefSource>
                <PMID Version="1">9593950</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Biol. 1998 Jul 30-Aug 13;8(16):923-6</RefSource>
                <PMID Version="1">9707404</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 1998 Jun;43(2):155-60</RefSource>
                <PMID Version="1">9710957</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Neurol. 1998 Dec;11(6):689-93</RefSource>
                <PMID Version="1">9870138</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2004 Nov 5;306(5698):1033-7</RefSource>
                <PMID Version="1">15528444</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr. 2005 May;135(5):1019-26</RefSource>
                <PMID Version="1">15867275</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurochem Res. 2005 Jun-Jul;30(6-7):927-35</RefSource>
                <PMID Version="1">16187227</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Clin Nutr. 2006 Feb;83(2):447S-455S</RefSource>
                <PMID Version="1">16470011</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosci. 2006 Feb 15;26(7):1961-70</RefSource>
                <PMID Version="1">16481428</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Thromb Hemost. 2006 Apr;32 Suppl 1:39-48</RefSource>
                <PMID Version="1">16673265</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Orthop Sci. 2006 May;11(3):326-31</RefSource>
                <PMID Version="1">16721539</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Neurobiol. 2006 Oct;16(5):501-7</RefSource>
                <PMID Version="1">16956757</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunol Today. 1999 Nov;20(11):477-9</RefSource>
                <PMID Version="1">10529772</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicol Teratol. 2000 Jan-Feb;22(1):133-40</RefSource>
                <PMID Version="1">10642122</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2000 Sep;57(1):87-94</RefSource>
                <PMID Version="1">10966514</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bull World Health Organ. 2000;78(9):1068-77</RefSource>
                <PMID Version="1">11019456</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Environ Health. 2000 Sep-Oct;55(5):330-5</RefSource>
                <PMID Version="1">11063408</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2000 Dec 15;290(5499):2155-9</RefSource>
                <PMID Version="1">11118151</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Behav Genet. 2000 Jul;30(4):285-93</RefSource>
                <PMID Version="1">11206083</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 2001 Oct 1;176(1):34-53</RefSource>
                <PMID Version="1">11578147</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2001 Nov;64(1):57-66</RefSource>
                <PMID Version="1">11606801</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biochem. 2001 Jul;223(1-2):27-33</RefSource>
                <PMID Version="1">11681719</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicol Teratol. 2001 Sep-Oct;23(5):489-95</RefSource>
                <PMID Version="1">11711252</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicol Teratol. 2001 Nov-Dec;23(6):511-8</RefSource>
                <PMID Version="1">11792521</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 2002 Jun 1;99(11):3892-904</RefSource>
                <PMID Version="1">12010786</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Res. 2002 May 24;937(1-2):74-82</RefSource>
                <PMID Version="1">12020865</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Behav Immun. 2002 Aug;16(4):477-92</RefSource>
                <PMID Version="1">12096892</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 2002 Oct;110(10):A574-80</RefSource>
                <PMID Version="1">12361937</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicol Teratol. 2002 Nov-Dec;24(6):711-7</RefSource>
                <PMID Version="1">12460653</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Res. 2002 Nov;90(3):191-9</RefSource>
                <PMID Version="1">12477464</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurochem Res. 2003 Jan;28(1):153-62</RefSource>
                <PMID Version="1">12587673</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Dev Neurosci. 2003 Oct;21(6):347-52</RefSource>
                <PMID Version="1">12927583</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Brain Behav. 2003 Aug;2(4):214-9</RefSource>
                <PMID Version="1">12953787</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Biochem Funct. 2003 Dec;21(4):345-53</RefSource>
                <PMID Version="1">14624473</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Med. 2004;55:209-22</RefSource>
                <PMID Version="1">14746518</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Immunol. 2004 Jun;5(6):575-81</RefSource>
                <PMID Version="1">15164017</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Neurosci. 2004;27:697-722</RefSource>
                <PMID Version="1">15217348</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Neurosci. 2004 Oct;27(10):621-6</RefSource>
                <PMID Version="1">15374674</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14168-73</RefSource>
                <PMID Version="1">15377787</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurosci Biobehav Rev. 2004 Sep;28(5):463-83</RefSource>
                <PMID Version="1">15465135</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1971 Jun 4;172(3987):1031-2</RefSource>
                <PMID Version="1">4929914</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Infect Immun. 1981 Jan;31(1):136-43</RefSource>
                <PMID Version="1">6971260</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Appl Pharmacol. 1983 Dec;71(3):342-52</RefSource>
                <PMID Version="1">6658785</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatrics. 1987 Nov;80(5):623-9</RefSource>
                <PMID Version="1">3670963</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Sci Total Environ. 1988 Jun 1;71(3):433-40</RefSource>
                <PMID Version="1">3406710</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicology. 1989 Fall;10(3):417-43</RefSource>
                <PMID Version="1">2696897</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Tokai J Exp Clin Med. 1989 Apr;14(2):147-52</RefSource>
                <PMID Version="1">2638762</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 1990 Jul 15;145(2):671-7</RefSource>
                <PMID Version="1">2164066</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Pharmacol. 1991 Feb 15;41(4):479-84</RefSource>
                <PMID Version="1">1671748</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fundam Appl Toxicol. 1991 Jul;17(1):75-82</RefSource>
                <PMID Version="1">1916082</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurotoxicology. 1993 Summer-Fall;14(2-3):131-6</RefSource>
                <PMID Version="1">8247388</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Environ Health Perspect. 1993 Dec;101(7):598-616</RefSource>
                <PMID Version="1">8143593</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Lett. 1995 Dec;82-83:399-405</RefSource>
                <PMID Version="1">8597084</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):227-32</RefSource>
                <PMID Version="1">8990190</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Genet. 2006;40:449-67</RefSource>
                <PMID Version="1">16953793</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Behav Brain Res. 2007 Jan 10;176(1):4-20</RefSource>
                <PMID Version="1">16971002</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Behav Brain Res. 2007 Jan 10;176(1):21-6</RefSource>
                <PMID Version="1">17097158</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Toxicol Sci. 2007 Jan;95(1):156-62</RefSource>
                <PMID Version="1">17047031</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurobiol Dis. 2007 Mar;25(3):614-22</RefSource>
                <PMID Version="1">17188500</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatrics. 2007 Mar;119(3):e650-8</RefSource>
                <PMID Version="1">17332184</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Neurosci. 2007 Apr;34(4):612-20</RefSource>
                <PMID Version="1">17292624</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6828-33</RefSource>
                <PMID Version="1">17420446</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Aggress Behav. 2007 Nov-Dec;33(6):545-51</RefSource>
                <PMID Version="1">17654688</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann N Y Acad Sci. 2007 Oct;1113:311-24</RefSource>
                <PMID Version="1">17584982</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Cell Biol. 2007 Oct;19(5):557-64</RefSource>
                <PMID Version="1">17942298</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000367">Age Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000374">Aggression</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000831">Animals, Newborn</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001522">Behavior, Animal</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D001921">Brain</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000196">embryology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000254">growth &amp; development</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016207">Cytokines</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004622">Embryo, Mammalian</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005106">Exploratory Behavior</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D022001">Focal Adhesions</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018507">Gene Expression Regulation, Developmental</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007854">Lead</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018782">Maze Learning</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009419">Nerve Tissue Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020411">Oligonucleotide Array Sequence Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011297">Prenatal Exposure Delayed Effects</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011956">Receptors, Cell Surface</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D045442">Rotarod Performance Test</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D012727">Sex Characteristics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D042442">Vascular Endothelial Growth Factors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS379079</OtherID>
        <OtherID Source="NLM">PMC3463649</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>9</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2012</Year>
                <Month>2</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2012</Year>
                <Month>4</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2012</Year>
                <Month>5</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>5</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>5</Month>
                <Day>23</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0161-813X(12)00093-9</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neuro.2012.04.017</ArticleId>
            <ArticleId IdType="pubmed">22609695</ArticleId>
            <ArticleId IdType="pmc">PMC3463649</ArticleId>
            <ArticleId IdType="mid">NIHMS379079</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15593312</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>04</Month>
            <Day>13</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0885-3185</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>20</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Movement disorders : official journal of the Movement Disorder Society</Title>
                <ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>403-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Overactive AMPA receptor-mediated transmission may be involved in the pathogenesis of levodopa-induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor-mediated transmission. In this study, the potential antidyskinetic action of topiramate was examined in the MPTP-lesioned marmoset model of Parkinson's disease and levodopa-induced dyskinesia. Topiramate significantly reduced levodopa-induced dyskinesia, without affecting the antiparkinsonian action of levodopa. Topiramate represents an exciting potential novel therapeutic approach to levodopa-induced dyskinesia in patients with Parkinson's disease.</AbstractText>
                <CopyrightInformation>Copyright 2004 Movement Disorder Society.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Silverdale</LastName>
                    <ForeName>Monty A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, Hope Hospital, Salford, Manchester, United Kingdom. msilverdale@yahoo.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nicholson</LastName>
                    <ForeName>S L</ForeName>
                    <Initials>SL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Crossman</LastName>
                    <ForeName>A R</ForeName>
                    <Initials>AR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brotchie</LastName>
                    <ForeName>J M</ForeName>
                    <Initials>JM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mov Disord</MedlineTA>
            <NlmUniqueID>8610688</NlmUniqueID>
            <ISSNLinking>0885-3185</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0H73WJJ391</RegistryNumber>
                <NameOfSubstance UI="C052342">topiramate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>30237-26-4</RegistryNumber>
                <NameOfSubstance UI="D005632">Fructose</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>46627O600J</RegistryNumber>
                <NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002144">Callithrix</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005632">Fructose</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020267">MPTP Poisoning</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2004</Year>
                <Month>12</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>8</Month>
                <Day>27</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2004</Year>
                <Month>12</Month>
                <Day>14</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.20345</ArticleId>
            <ArticleId IdType="pubmed">15593312</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3968329</PMID>
        <DateCreated>
            <Year>1985</Year>
            <Month>02</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1985</Year>
            <Month>02</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0091-6749</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>75</Volume>
                    <Issue>1 Pt 1</Issue>
                    <PubDate>
                        <Year>1985</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of allergy and clinical immunology</Title>
                <ISOAbbreviation>J. Allergy Clin. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Bitolterol and albuterol metered-dose aerosols: comparison of two long-acting beta 2-adrenergic bronchodilators for treatment of asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>55-62</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In this double-blind, parallel, single-dose study, bitolterol mesylate aerosol (three sprays, 1.11 mg) and albuterol aerosol (two sprays, 180 mcg) were compared for efficacy of bronchodilation in 120 adolescent and young adult patients with moderate to severe asthma. All patients required regular medications for asthma control. None was steroid dependent. Both medications gave effective bronchodilation within 5 min with maximum effect at 30 to 60 min. Mean percent increase in forced expiratory volume in 1 sec (FEV1) over baseline was higher for bitolterol than for albuterol at all test times up to 8 hr after a dose at which time 20% mean percent increase of FEV1 over baseline was still present in the bitolterol-treated patients. With albuterol mean percent increase in FEV1 fell to 15% over baseline at 5 hr after a dose. Differences in FEV1 increase between the two treatment groups were statistically significant at 4 to 8 hr after a dose. Patients with baseline FEV1 less than 50% of predicted normal had a response to bitolterol that was higher than that observed with albuterol treatment (p less than 0.1). Mean maximum percent increase in FEV1 and median duration of bronchodilation were greater with bitolterol than with albuterol, but the differences were not statistically significant. Both bitolterol aerosol and albuterol aerosol were demonstrated to be safe, effective, and long-acting bronchodilating agents. Both bitolterol and albuterol administered by aerosol had a rapid onset, and the maximum degree of bronchodilation was comparable. However, at the doses studied, bitolterol produced significantly higher increase in FEV1 over baseline at longer times after medication than did albuterol.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Orgel</LastName>
                    <ForeName>H A</ForeName>
                    <Initials>HA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kemp</LastName>
                    <ForeName>J P</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tinkelman</LastName>
                    <ForeName>D G</ForeName>
                    <Initials>DG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Webb</LastName>
                    <ForeName>D R</ForeName>
                    <Initials>DR</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D018848">Controlled Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Allergy Clin Immunol</MedlineTA>
            <NlmUniqueID>1275002</NlmUniqueID>
            <ISSNLinking>0091-6749</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000336">Aerosols</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D004983">Ethanolamines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9KY0QXD6LI</RegistryNumber>
                <NameOfSubstance UI="C011685">bitolterol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>QF8SVZ843E</RegistryNumber>
                <NameOfSubstance UI="D000420">Albuterol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000336">Aerosols</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000420">Albuterol</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001249">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001993">Bronchodilator Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004983">Ethanolamines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005541">Forced Expiratory Volume</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006261">Headache</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006339">Heart Rate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014202">Tremor</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1985</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>3</Month>
                <Day>28</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1985</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3968329</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18486454</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>06</Month>
            <Day>24</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>09</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2010</Year>
            <Month>09</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0920-9964</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>102</Volume>
                    <Issue>1-3</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Jul</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Schizophrenia research</Title>
                <ISOAbbreviation>Schizophr. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: association with the metabolic syndrome in patients?</ArticleTitle>
            <Pagination>
                <MedlinePgn>352-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.schres.2008.03.018</ELocationID>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Drexhage</LastName>
                    <ForeName>Roosmarijn C</ForeName>
                    <Initials>RC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Padmos</LastName>
                    <ForeName>Roos C</ForeName>
                    <Initials>RC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Wit</LastName>
                    <ForeName>Harm</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Versnel</LastName>
                    <ForeName>Marjan A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hooijkaas</LastName>
                    <ForeName>Herbert</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van der Lely</LastName>
                    <ForeName>Aart-Jan</ForeName>
                    <Initials>AJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Beveren</LastName>
                    <ForeName>Nico</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>deRijk</LastName>
                    <ForeName>Roel H</ForeName>
                    <Initials>RH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cohen</LastName>
                    <ForeName>Dan</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2008</Year>
                <Month>05</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Schizophr Res</MedlineTA>
            <NlmUniqueID>8804207</NlmUniqueID>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018932">Chemokine CCL2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D002630">Chemotactic Factors</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018932">Chemokine CCL2</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002630">Chemotactic Factors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002908">Chronic Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015897">Comorbidity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D035061">Control Groups</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D024821">Metabolic Syndrome X</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D009426">Netherlands</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015995">Prevalence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012559">Schizophrenia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2008</Year>
                <Month>3</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>3</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>5</Month>
                <Day>20</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0920-9964(08)00159-X</ArticleId>
            <ArticleId IdType="doi">10.1016/j.schres.2008.03.018</ArticleId>
            <ArticleId IdType="pubmed">18486454</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21184191</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>04</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>08</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1534-4681</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>18</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Annals of surgical oncology</Title>
                <ISOAbbreviation>Ann. Surg. Oncol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1506-11</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1245/s10434-010-1488-z</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Currently, complete surgical resection is the only curative option for medullary thyroid cancer (MTC). Previous work has shown the Notch pathway is a potent tumor suppressor in MTC and that resveratrol activates the Notch pathway in carcinoid cancer, a related neuroedocrine malignancy. In this study, we hypothesized that the effects observed on carcinoid cells could be extended to MTC.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">MTC cells treated with varying doses of resveratrol were assayed for viability by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay. Western blot analysis for achaete-scute complex-like 1 (ASCL1), chromogranin A (CgA), full-length and cleaved caspase 3, and poly-ADP ribose polymerase (PARP) was performed. Quantitative real-time polymerase chain reaction (qPCR) was used to measure relative mRNA expression.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Treatment with resveratrol resulted in growth suppression and an increase in the cleavage of caspase-3 and PARP. A dose-dependent inhibition of ASCL1, a neuroedocrine transcription factor, was observed at the protein and mRNA levels. Protein levels of CgA, a marker of hormone secretion, were also reduced after treatment with resveratrol. A dose-dependent induction of Notch2 mRNA was observed by qPCR.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Resveratrol suppresses in vitro growth, likely through apoptosis, as demonstrated by cleavage of caspase-3 and PARP. Furthermore, resveratrol decreased neuroedocrine markers ASCL1 and chromogranin A. Induction of Notch2 mRNA suggests that this pathway may be central in the anti-MTC effects observed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Truong</LastName>
                    <ForeName>Matthew</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, University of Wisconsin, Madison, WI, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cook</LastName>
                    <ForeName>Mackenzie R</ForeName>
                    <Initials>MR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pinchot</LastName>
                    <ForeName>Scott N</ForeName>
                    <Initials>SN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kunnimalaiyaan</LastName>
                    <ForeName>Muthusamy</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Herbert</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DK 062709-0401</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA109053</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA109053</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA109053-01A2</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA109053-02</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA109053-03</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA109053-04</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA109053-05</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA121115</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA121115</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA121115-01A2</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA121115-02</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA121115-02S1</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA121115-03</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T35 DK062709</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T35 DK062709-03</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T35 DK062709-04</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T35 DK062709-05</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <Agency>Howard Hughes Medical Institute</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>24</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Ann Surg Oncol</MedlineTA>
            <NlmUniqueID>9420840</NlmUniqueID>
            <ISSNLinking>1068-9265</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C065500">ASCL1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051792">Basic Helix-Loop-Helix Transcription Factors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D053379">Chromogranin A</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497764">NOTCH2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051883">Receptor, Notch2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013267">Stilbenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.4.2.30</RegistryNumber>
                <NameOfSubstance UI="D011065">Poly(ADP-ribose) Polymerases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.4.22.-</RegistryNumber>
                <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>Q369O8926L</RegistryNumber>
                <NameOfSubstance UI="C059514">resveratrol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Surgery. 2006 Dec;140(6):1009-14; discussion 1014-5</RefSource>
                <PMID Version="1">17188151</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Surg Oncol. 2007 May;33(4):493-7</RefSource>
                <PMID Version="1">17125960</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncologist. 2007 Aug;12(8):942-51</RefSource>
                <PMID Version="1">17766653</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncologist. 2008 Feb;13(2):98-104</RefSource>
                <PMID Version="1">18305053</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Surg. 2008 Jun;247(6):1036-40</RefSource>
                <PMID Version="1">18520232</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Biol Markers. 2008 Apr-Jun;23(2):129-31</RefSource>
                <PMID Version="1">18629788</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Surg Oncol. 2008 Sep;15(9):2600-5</RefSource>
                <PMID Version="1">18563491</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Prev Res (Phila). 2009 May;2(5):409-18</RefSource>
                <PMID Version="1">19401532</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Surg Res. 2010 Apr;159(2):640-4</RefSource>
                <PMID Version="1">19394967</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 2011 Apr 1;117(7):1386-98</RefSource>
                <PMID Version="1">21425138</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Gastroenterol Hepatol. 2001 Jan;13(1):55-8</RefSource>
                <PMID Version="1">11204811</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2001 Apr 1;61(7):3062-70</RefSource>
                <PMID Version="1">11306488</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2001 Apr 1;61(7):3200-5</RefSource>
                <PMID Version="1">11306509</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Oncol. 2001;12 Suppl 2:S69-72</RefSource>
                <PMID Version="1">11762355</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr. 2002 Feb;132(2):257-60</RefSource>
                <PMID Version="1">11823587</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Otolaryngol Head Neck Surg. 2003 Jan;128(1):115-23</RefSource>
                <PMID Version="1">12574769</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosci. 2003 Sep 3;23(22):7967-73</RefSource>
                <PMID Version="1">12954857</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Surgery. 2003 Dec;134(6):866-71; discussion 871-3</RefSource>
                <PMID Version="1">14668716</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mod Pathol. 2004 Feb;17(2):222-9</RefSource>
                <PMID Version="1">14657947</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Lett. 2004 Feb 20;204(2):159-69</RefSource>
                <PMID Version="1">15013215</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>World J Surg. 2004 Apr;28(4):387-92</RefSource>
                <PMID Version="1">14994141</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2004 Oct 15;64(20):7183-90</RefSource>
                <PMID Version="1">15492230</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Growth Differ. 1997 Jun;8(6):677-86</RefSource>
                <PMID Version="1">9186001</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Oncol. 1997 Jul;8(7):685-90</RefSource>
                <PMID Version="1">9296223</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Coll Surg. 1998 Jul;187(1):88-92; discussion 92-3</RefSource>
                <PMID Version="1">9660030</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Oncol. 1998 Jul;9(7):695-701</RefSource>
                <PMID Version="1">9739433</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Surg Oncol. 2005 Mar 1;89(3):122-9</RefSource>
                <PMID Version="1">15719378</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Thyroid. 2005 Jun;15(6):511-21</RefSource>
                <PMID Version="1">16029117</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Drug Discov. 2006 Jun;5(6):493-506</RefSource>
                <PMID Version="1">16732220</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2006 Dec 29;281(52):39819-30</RefSource>
                <PMID Version="1">17090547</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000972">Antineoplastic Agents, Phytogenic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051792">Basic Helix-Loop-Helix Transcription Factors</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018276">Carcinoma, Medullary</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053148">Caspase 3</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D045744">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D049109">Cell Proliferation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D053379">Chromogranin A</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009490">Neurosecretory Systems</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011065">Poly(ADP-ribose) Polymerases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012333">RNA, Messenger</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051883">Receptor, Notch2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013267">Stilbenes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013964">Thyroid Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS249400</OtherID>
        <OtherID Source="NLM">PMC3078954</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2010</Year>
                <Month>8</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2010</Year>
                <Month>12</Month>
                <Day>25</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>8</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1245/s10434-010-1488-z</ArticleId>
            <ArticleId IdType="pubmed">21184191</ArticleId>
            <ArticleId IdType="pmc">PMC3078954</ArticleId>
            <ArticleId IdType="mid">NIHMS249400</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6072340</PMID>
        <DateCreated>
            <Year>1967</Year>
            <Month>12</Month>
            <Day>15</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1967</Year>
            <Month>12</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>09</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0098-7484</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>201</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1967</Year>
                        <Month>Jul</Month>
                        <Day>10</Day>
                    </PubDate>
                </JournalIssue>
                <Title>JAMA</Title>
                <ISOAbbreviation>JAMA</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prolonged coma after acetohexamide ingestion.</ArticleTitle>
            <Pagination>
                <MedlinePgn>141-2</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cowen</LastName>
                    <ForeName>D L</ForeName>
                    <Initials>DL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burtis</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Youmans</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>JAMA</MedlineTA>
            <NlmUniqueID>7501160</NlmUniqueID>
            <ISSNLinking>0098-7484</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>QGC8W08I6I</RegistryNumber>
                <NameOfSubstance UI="D000092">Acetohexamide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000092">Acetohexamide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003128">Coma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007003">Hypoglycemia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1967</Year>
                <Month>7</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1967</Year>
                <Month>7</Month>
                <Day>10</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1967</Year>
                <Month>7</Month>
                <Day>10</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6072340</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3738227</PMID>
        <DateCreated>
            <Year>1986</Year>
            <Month>09</Month>
            <Day>18</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1986</Year>
            <Month>09</Month>
            <Day>18</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0034-5288</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>40</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>1986</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Research in veterinary science</Title>
                <ISOAbbreviation>Res. Vet. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pulmonary function changes induced by experimental dichlorvos toxicosis in calves.</ArticleTitle>
            <Pagination>
                <MedlinePgn>318-21</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Clinical and pulmonary function changes induced by intravenous dichlorvos (2,2-dichlorvinyldimethyl phosphate) (DDVP) toxicosis, and reversibility of these changes after atropine treatment were investigated in six Friesian calves one to three months old. From one minute after dosage, all animals showed severe respiratory distress, excitation, weakness, muscle fasciculation and cholinesterase inhibition. Decrease in dynamic lung compliance and arterial oxygen tension and increase in total pulmonary resistance, viscous work of breathing and alveolar arterial oxygen gradient were highly significant (P less than 0.01). On the other hand, body secretions, heart rate, respiratory rate, tidal volume and arterial carbon dioxide tension were not significantly affected by DDVP injection. Atropine promptly and completely reversed these changes, except for muscle fasciculations, central depression and cholinesterase inhibition which disappeared progressively within 24 hours.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lekeux</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kyavu</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Clercx</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ansay</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Res Vet Sci</MedlineTA>
            <NlmUniqueID>0401300</NlmUniqueID>
            <ISSNLinking>0034-5288</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>7C0697DR9I</RegistryNumber>
                <NameOfSubstance UI="D001285">Atropine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7U370BPS14</RegistryNumber>
                <NameOfSubstance UI="D004006">Dichlorvos</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.1.8</RegistryNumber>
                <NameOfSubstance UI="D002802">Cholinesterases</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001285">Atropine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002417">Cattle</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002418">Cattle Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002802">Cholinesterases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004006">Dichlorvos</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004912">Erythrocytes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011659">Pulmonary Gas Exchange</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012119">Respiration</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1986</Year>
                <Month>5</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1986</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1986</Year>
                <Month>5</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3738227</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11325394</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>04</Month>
            <Day>30</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2001</Year>
            <Month>07</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0091-3057</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>68</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2001</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pharmacology, biochemistry, and behavior</Title>
                <ISOAbbreviation>Pharmacol. Biochem. Behav.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Differential effects of 7-OH-DPAT on the development of behavioral sensitization to apomorphine and cocaine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>417-26</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The primary objective of this study was to determine whether concurrent treatments with a low dose of the dopamine D(3)-preferring receptor agonist 7-OH-DPAT would attenuate the development of behavioral sensitization to the indirect dopamine receptor agonist, cocaine, or the direct dopamine receptor agonist, apomorphine. In two experiments, male Wistar rats (250-350 g) were given seven daily injections of 7-OH-DPAT (0.05 mg/kg sc) or vehicle in combination with either cocaine (15 mg/kg ip), apomorphine (1.0 mg/kg sc), or vehicle. After the injections, the rats were tested for activity in photocell arenas for 40 min, and three measures of motor behavior (distance traveled, rearing, and stereotypy) were recorded at 10-min intervals. A total of 24 h after the last preexposure session, all rats were given a challenge injection of either cocaine (10.0 mg/kg ip, Experiment 1) or apomorphine (1.0 mg/kg sc, Experiment 2) and tested for activity. Major findings were as follows: (a) 7-OH-DPAT treatments alone suppressed all measures of locomotor activity and did not affect subsequent behavioral sensitivity to either cocaine or apomorphine; (b) cocaine treatments acutely increased all measures of activity, and repeated treatments produced behavioral sensitization to the horizontal locomotor-activating effects of cocaine; (c) apomorphine treatments alone increased horizontal activity and stereotypy but completely abolished rearing behavior; (d) like cocaine, repeated treatments with apomorphine induced behavioral sensitization; (e) concurrent treatments of 7-OH-DPAT with cocaine acutely attenuated cocaine-induced increases in motor behavior but enhanced the development of behavioral sensitization to cocaine; and (f) concurrent 7-OH-DPAT treatments did not significantly affect either the acute or chronic effects of apomorphine. It is evident from these results that concurrent treatment with 7-OH-DPAT does not block the development of behavioral sensitization to either cocaine or apomorphine. Moreover, the differential acute and chronic effects of 7-OH-DPAT on cocaine- and apomorphine-induced hyperactivity appear to be mediated by dopamine autoreceptor stimulation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mattingly</LastName>
                    <ForeName>B A</ForeName>
                    <Initials>BA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Psychology, Morehead State University, 601 Ginger Hall, Morehead, KY 40351-1689, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caudill</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abel</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>DA 09687</GrantID>
                    <Acronym>DA</Acronym>
                    <Agency>NIDA NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Pharmacol Biochem Behav</MedlineTA>
            <NlmUniqueID>0367050</NlmUniqueID>
            <ISSNLinking>0091-3057</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018765">Dopamine Uptake Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C493595">Drd3 protein, rat</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050637">Receptors, Dopamine D3</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>74938-11-7</RegistryNumber>
                <NameOfSubstance UI="C031349">7-hydroxy-2-N,N-dipropylaminotetralin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>I5Y540LHVR</RegistryNumber>
                <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>N21FAR7B4S</RegistryNumber>
                <NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001058">Apomorphine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001522">Behavior, Animal</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018765">Dopamine Uptake Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005110">Extracellular Space</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017448">Receptors, Dopamine D2</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000819">agonists</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050637">Receptors, Dopamine D3</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013239">Stereotyped Behavior</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013764">Tetrahydronaphthalenes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2001</Year>
                <Month>4</Month>
                <Day>28</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>7</Month>
                <Day>20</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2001</Year>
                <Month>4</Month>
                <Day>28</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11325394</ArticleId>
            <ArticleId IdType="pii">S0091-3057(00)00471-8</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12060505</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>06</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>08</Month>
            <Day>06</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0954-6634</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of dermatological treatment</Title>
                <ISOAbbreviation>J Dermatolog Treat</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Fluconazole versus ketoconazole in the treatment of tinea versicolor.</ArticleTitle>
            <Pagination>
                <MedlinePgn>73-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A number of effective topical therapies are available for the treatment of tinea versicolor (TV). However, topical antifungals are difficult to apply to a large body surface area and for this reason TV is perhaps more easily treated with systemic agents.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 128 patients with TV, aged 15-55 years, were entered into a randomized, double-blind, clinical trial comparing the efficacy and tolerance of two regimens of oral treatment for TV. The patients were randomly divided in two groups: group 1 received two 150 mg capsules of fluconazole in a single dose repeated weekly for 2 weeks; and group 2 received two 200 mg tablets of ketoconazole in a single dose repeated weekly for 2 weeks. Diagnosis of TV was made clinically by direct KOH preparation and Wood's lamp examination.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 128 patients, 100 completed the study and no major side-effects were noted between the two treatment regimens. Results of the study showed no significant differences in efficacy, safety and tolerability between the two treatment regimens. The maximal cure rate was achieved at 8 weeks from the start of treatment and decreased slightly afterwards.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Fluconazole and ketoconazole demonstrated similar efficacy in the treatment of TV. We also demonstrated a lack of correlation between mycological cure and hypopigmentation at the end of treatment (2 weeks) and the usefulness of Wood's lamp examination in detecting cure of TV.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Farschian</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Dermatology, Hamadan University of Medical Sciences, Hamadan, Iran. beh1976@yahoo.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yaghoobi</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Samadi</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Dermatolog Treat</MedlineTA>
            <NlmUniqueID>8918133</NlmUniqueID>
            <ISSNLinking>0954-6634</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>8VZV102JFY</RegistryNumber>
                <NameOfSubstance UI="D015725">Fluconazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>R9400W927I</RegistryNumber>
                <NameOfSubstance UI="D007654">Ketoconazole</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000935">Antifungal Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005076">Exanthema</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005221">Fatigue</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015725">Fluconazole</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006261">Headache</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007654">Ketoconazole</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008290">Malassezia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012449">Safety</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014010">Tinea Versicolor</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000382">microbiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>6</Month>
                <Day>13</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>8</Month>
                <Day>7</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>6</Month>
                <Day>13</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12060505</ArticleId>
            <ArticleId IdType="doi">10.1080/095466302317584421</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12422484</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>11</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>11</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>06</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0755-4982</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>31</Volume>
                    <Issue>33</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Oct</Month>
                        <Day>12</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Presse médicale (Paris, France : 1983)</Title>
                <ISOAbbreviation>Presse Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Edematous syndrome and alithiasic cholecystitis induced by gabapentin].</ArticleTitle>
            <Pagination>
                <MedlinePgn>1559</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Guéguen</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guy</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cartry</LastName>
                    <ForeName>O</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bouchou</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gouilloud</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cathébras</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>fre</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Syndrome oedémateux et cholécystite alithiasique induits par la gabapentine.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>France</Country>
            <MedlineTA>Presse Med</MedlineTA>
            <NlmUniqueID>8302490</NlmUniqueID>
            <ISSNLinking>0755-4982</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000085">Acetates</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000588">Amines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003509">Cyclohexanecarboxylic Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>56-12-2</RegistryNumber>
                <NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6CW7F3G59X</RegistryNumber>
                <NameOfSubstance UI="C040029">gabapentin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000085">Acetates</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D000588">Amines</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000927">Anticonvulsants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002764">Cholecystitis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D003509">Cyclohexanecarboxylic Acids</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004487">Edema</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004827">Epilepsy</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D005680">gamma-Aminobutyric Acid</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>11</Month>
                <Day>26</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12422484</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">9026843</PMID>
        <DateCreated>
            <Year>1997</Year>
            <Month>02</Month>
            <Day>19</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1997</Year>
            <Month>02</Month>
            <Day>19</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0300-8932</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>49</Volume>
                    <Issue>12</Issue>
                    <PubDate>
                        <Year>1996</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Revista española de cardiología</Title>
                <ISOAbbreviation>Rev Esp Cardiol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Sinus bradycardia secondary to systemic pentamidine].</ArticleTitle>
            <Pagination>
                <MedlinePgn>919-20</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Systemic side effects caused by parenteral pentamidine are frequent. They can be severe and life-threatening. Intravenous pentamidine may cause a variety of abnormalities in the cardiac conduction system as tachyarrhythmias, hypotension and/or non-specific ECG changes (a long corrected QT interval). There is only one case of previously reported bradyarrhythmias in an HIV-infected patient. We present a new adverse effect associated with intravenous pentamidine therapy, and to the best of our knowledge, this is the first reported case of sinus bradycardia in a patient who is not HIV-infected.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Izquierdo Patrón</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Sección de Neumología, Hospital General de Albacete.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lafuente</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haro Estarriol</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arévalo González</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>spa</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016454">Review</PublicationType>
            </PublicationTypeList>
            <VernacularTitle>Bradicardia sinusal secundaria a pentamidina sistémica.</VernacularTitle>
        </Article>
        <MedlineJournalInfo>
            <Country>SPAIN</Country>
            <MedlineTA>Rev Esp Cardiol</MedlineTA>
            <NlmUniqueID>0404277</NlmUniqueID>
            <ISSNLinking>0300-8932</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>673LC5J4LQ</RegistryNumber>
                <NameOfSubstance UI="D010419">Pentamidine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CitationSubset>X</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001919">Bradycardia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002908">Chronic Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018023">HIV Seronegativity</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007275">Injections, Intravenous</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008180">Lupus Erythematosus, Systemic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010419">Pentamidine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011020">Pneumonia, Pneumocystis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <NumberOfReferences>7</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1996</Year>
                <Month>12</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1996</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1996</Year>
                <Month>12</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">9026843</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10792356</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0954-7894</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>30</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2000</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</Title>
                <ISOAbbreviation>Clin. Exp. Allergy</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Association between HLA genes and susceptibility to toluene diisocyanate-induced asthma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>651-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Only a small proportion of subjects exposed to isocyanates develop occupational asthma, suggesting individual predisposition. The human leucocyte antigen (HLA) class II molecules may play a crucial role in the development of the immune response to isocyanates.</AbstractText>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To investigate the role of HLA class II molecules in the development of toluene diisocyanate (TDI)-induced asthma.</AbstractText>
                <AbstractText Label="SUBJECTS" NlmCategory="METHODS">Sixty-seven asthmatic subjects and 27 asymptomatic exposed subjects (controls) were typed at the HLA class II DQA1, DQB1 and DRB1 loci by polymerase chain reaction (PCR)-based techniques.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The frequencies of DQA1*0104 and DQB1*0503 were significantly increased in asthmatics compared with asymptomatic exposed subjects, while DQA1*0101 and DQB1*0501 were significantly increased in asymptomatic exposed subjects. No significant difference was found in the distribution of DRB1 alleles between asthmatics and controls.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results of this study indicate that HLA-regulated immune mechanisms are involved in TDI-induced asthma and that, in exposed subjects, specific factors may increase or decrease the risk of developing disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mapp</LastName>
                    <ForeName>C E</ForeName>
                    <Initials>CE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Occupational Medicine, University of Padova, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beghè</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Balboni</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zamorani</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Padoan</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jovine</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baricordi</LastName>
                    <ForeName>O R</ForeName>
                    <Initials>OR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fabbri</LastName>
                    <ForeName>L M</ForeName>
                    <Initials>LM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Clin Exp Allergy</MedlineTA>
            <NlmUniqueID>8906443</NlmUniqueID>
            <ISSNLinking>0954-7894</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006683">HLA-DQ Antigens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D059848">HLA-DQ alpha-Chains</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D059866">HLA-DQ beta-Chains</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C069050">HLA-DQA1 antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C057615">HLA-DQbeta antigen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006684">HLA-DR Antigens</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>17X7AFZ1GH</RegistryNumber>
                <NameOfSubstance UI="D014051">Toluene 2,4-Diisocyanate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001249">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D005802">Genes, MHC Class II</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020022">Genetic Predisposition to Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006683">HLA-DQ Antigens</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059848">HLA-DQ alpha-Chains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059866">HLA-DQ beta-Chains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006684">HLA-DR Antigens</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059811">HLA-DRB1 Chains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009784">Occupational Diseases</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014051">Toluene 2,4-Diisocyanate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2000</Year>
                <Month>5</Month>
                <Day>3</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2000</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>11</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2000</Year>
                <Month>5</Month>
                <Day>3</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10792356</ArticleId>
            <ArticleId IdType="pii">cea807</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19664544</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>08</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>10</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1873-5150</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>41</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pediatric neurology</Title>
                <ISOAbbreviation>Pediatr. Neurol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Mesial temporal sclerosis after posterior reversible encephalopathy syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn>226-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pediatrneurol.2009.03.007</ELocationID>
            <Abstract>
                <AbstractText>Neither intrathecal methotrexate nor posterior reversible encephalopathy syndrome has previously been reported to result in mesial temporal sclerosis. Described here is the case of a boy with no risk factors for mesial temporal sclerosis who presented with posterior reversible encephalopathy syndrome and partial complex seizures 8 days after initiation of intrathecal methotrexate for treatment of Burkitt lymphoma, and who ultimately progressed to intractable temporal lobe epilepsy due to left mesial temporal sclerosis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Aboian</LastName>
                    <ForeName>Mariam S</ForeName>
                    <Initials>MS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Mayo Medical School, Rochester, Minnesota, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Junna</LastName>
                    <ForeName>Mithri R</ForeName>
                    <Initials>MR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Krecke</LastName>
                    <ForeName>Karl N</ForeName>
                    <Initials>KN</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wirrell</LastName>
                    <ForeName>Elaine C</ForeName>
                    <Initials>EC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Pediatr Neurol</MedlineTA>
            <NlmUniqueID>8508183</NlmUniqueID>
            <ISSNLinking>0887-8994</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>YL5FZ2Y5U1</RegistryNumber>
                <NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001927">Brain Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002051">Burkitt Lymphoma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D038524">Diffusion Magnetic Resonance Imaging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004833">Epilepsy, Temporal Lobe</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008727">Methotrexate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012598">Sclerosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D013702">Temporal Lobe</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2008</Year>
                <Month>10</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2009</Year>
                <Month>2</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>12</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>10</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0887-8994(09)00144-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pediatrneurol.2009.03.007</ArticleId>
            <ArticleId IdType="pubmed">19664544</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">10611609</PMID>
        <DateCreated>
            <Year>2000</Year>
            <Month>01</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2000</Year>
            <Month>01</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0269-3879</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>13</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>1999</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Biomedical chromatography : BMC</Title>
                <ISOAbbreviation>Biomed. Chromatogr.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Enantiomer-specific high-performance liquid chromatography with fluorescence detection of methamphetamines in abusers' hair and urine.</ArticleTitle>
            <Pagination>
                <MedlinePgn>543-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Enantiomer-specific high-performance liquid chromatography with fluorescence detection using 4-(4,5-diphenyl-1H-imidazol-2-yl)-benzoyl chloride as a fluorescence labeling reagent was applied to determine methamphetamine and its metabolites in abusers' hair and urine. Hair samples were segmentally analyzed based on 1 cm long segments. In four hair samples, only the S(+)-enantiomers of methamphetamine and its N-demethylated metabolite, S(+)-amphetamine were detected. Satisfactory correlation (r = 0.901) between the results of high-performance liquid chromatography-fluorescence and those of gas chromatography-nitrogen phosphorous detection was obtained (n = 19). In an abuser's urine sample, the S(+)- and R(-)-enantiomers of methamphetamine, amphetamine and para-hydroxymethamphetamine were detected. The degree of N-demethylation of S(+)-methamphetamine into the corresponding metabolite of amphetamine was significantly higher than that of the R(-)-enantiomer.</AbstractText>
                <CopyrightInformation>Copyright 1999 John Wiley &amp; Sons, Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Al-Dirbashi</LastName>
                    <ForeName>O</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>School of Pharmaceutical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wada</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kuroda</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Inuduka</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nakashima</LastName>
                    <ForeName>K</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D003160">Comparative Study</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>ENGLAND</Country>
            <MedlineTA>Biomed Chromatogr</MedlineTA>
            <NlmUniqueID>8610241</NlmUniqueID>
            <ISSNLinking>0269-3879</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>44RAL3456C</RegistryNumber>
                <NameOfSubstance UI="D008694">Methamphetamine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002849">Chromatography, Gas</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002851">Chromatography, High Pressure Liquid</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006197">Hair</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008694">Methamphetamine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013050">Spectrometry, Fluorescence</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013237">Stereoisomerism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019966">Substance-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1999</Year>
                <Month>12</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1999</Year>
                <Month>12</Month>
                <Day>28</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1999</Year>
                <Month>12</Month>
                <Day>28</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">10611609</ArticleId>
            <ArticleId IdType="pii">10.1002/(SICI)1099-0801(199912)13:8&lt;543::AID-BMC925&gt;3.0.CO;2-7</ArticleId>
            <ArticleId IdType="doi">10.1002/(SICI)1099-0801(199912)13:8&lt;543::AID-BMC925&gt;3.0.CO;2-7</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
